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Summary of the thesis  
This thesis comprises four chapters; Literature Review, Materials and Methods, 
Results and Discussion/Conclusions. It represents the work conducted by the 
candidate during the period April 2013 and May 2015.  
 
Chapter one is a critical review of the scientific literature related to iodine and iodine 
deficiency. Firstly, it highlights that Tasmania has had a history of thyroid disease in 
the community, including iodine deficiency. More recently, a Tasmanian study 
reported that children born to iodine-deficient mothers suffered impaired cognitive 
development. 
 
Secondly, it examines the changes occur in thyroid function during pregnancy and 
whether these have any influence on pregnancy outcomes. It further analyses 
different opinions regarding the role of iron in pregnancy as well as the effect of iron 
deficiency anaemia on pregnancy. It also explores the feasibility of iodine level 
surveillance in childbearing women as well as potential applications of cord blood in 
foetal thyroid assessment. 
  
Studies of thyroid function and iron deficiency during pregnancy in Tasmania are 
limited. Furthermore, the application of general screening for thyroid 
function/dysfunction during and prior to pregnancy remains controversial. Thus, the 
overall aim of the present study was to determine the incidence of thyroid 
dysfunction during pregnancy and to investigate whether any possible relationships 
exist between low thyroid status and complications occurred during pregnancy and 
labour.  
XIV 
 
 
Chapter two summarises the study design, subject recruitment, materials, and 
methods used during this study. It further describes sample processing, tests used 
during screening, including full blood count, iron studies, maternal, foetal thyroid 
function tests (TSH, FT4, FT3 and anti-thyroid peroxidase antibodies), and urinary 
iodine concentration.  
 
The results chapter primarily presents the data of the study in a series of tables and 
figures, including description of the study population and study outcomes. A 
response rate of 28.9% was demonstrated, with 609/636 (95.7%) of participants 
successfully screened for thyroid status. Next, incidence of thyroid abnormalities in 
the study population was demonstrated; 22 (9 with TSH >3 mU/L, 13 with TSH 2.5-
3mU/L) and 75 with FT4<8.93.4%, representing 3.4% of low thyroid status and 
12.3% of isolated hypothyroxinemia, respectively. 
 
Furthermore, possible association of maternal and foetal complications with the 
thyroid status was also shown; prolonged labour (IRR 3.31; 95% CI 1.13 to 9.69; 
P<0.05) and gestational diabetes (IRR 1.69; 95% CI 0.55-5.25; P=0.36). It also 
demonstrates that the study population is iodine deficient; median UIC=117µg/L 
with 11.2% of them having developed isolated hypothyroxinemia (FT4<8.9 mU/L) 
during pregnancy. 
 
Additionally, CB-TSH results of 402/615 (65%) of babies born to this study cohort 
was analysed. It shows a significant decrease of TSH level in the cord blood of 
babies born to participants with bleeding complications (APH/IPH) (Mean (SD) 
XV 
 
4.91(2.16); 95% CI -5.48 to -2.48; P<0.001) compared to CB-TSH of babies born to 
participants without bleeding (Mean (SD) 9.40(5.97)). Although this may not reflect 
abnormal foetal thyroid function, it does demonstrate a strong thyroid reaction to 
maternal ante-/intra-partum bleeding that needs further investigations. 
 
The last chapter discusses the main outcomes of the study and shows how the 
incidence of low thyroid function of this study is unexpectedly low but in line with 
international figures. It also discusses the importance of iodine surveillance as well 
as general screening for thyroid function prior or at early pregnancy. The chapter 
concludes by emphasising the importance of the incidence of thyroid disorder in this 
population in Northern Tasmania, and the possibility of an increased incidence of 
antenatal complication in association with low thyroid status being equivocal. Since 
the main limitation of this study was the small sample size, more statistically 
significant outcomes are anticipated with larger scale studies in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
1 LITERATURE REVIEW 
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1.1 Introduction 
Management of a swollen thyroid gland (Goitre) was first explained by the ancient 
Chinese 3500 years ago (Temple, 1999). Iodine deficiency was later recognised to be 
the main cause of goitre in some areas of mountainous terrain and other inland places 
(Vanderpas, 2006, Richards and Stewart, 2007, Zimmermann, 2010). Tasmania has a 
strong history of  battling  with iodine deficiency and goitre (Gibson, 2006). The 
magnitude of the disease was clearly evidenced by pictures and reports in a 
Tasmanian publication (Richards and Stewart, 2007). Furthermore, early reports of 
medical and surgical treatment for goitre in the Launceston General Hospital (LGH), 
were made in late 19th century (Richards and Stewart, 2007). It has been advised that 
any health condition caused by iodine deficiency which is preventable by iodine 
supplementation is now classified as an Iodine Deficiency Disorder (IDD), by the 
World Health Organisation (WHO) (Andersson et al., 2005, Andersson et al., 2012).  
  
The prevalence of thyroid diseases in a form of subclinical hypothyroidism during 
pregnancy is estimated to be 1.5-4% (Allan et al., 2000, Casey et al., 2005, Negro 
and Mestman, 2011). While the physiology and pathology of the thyroid gland has 
been well studied, results of thyroid function tests in laboratories varied considerably 
during pregnancy (Burrow, 1990, Glinoer, 1999, Casey and Leveno, 2006, Gärtner, 
2009, Hall, 2010). Pregnancy was described as a state of significant hormonal 
changes that could result in elevated thyroid stimulating hormone (TSH) and 
suppressed thyroxin (T4) (Glinoer, 1999). Thus, maintaining balance between these 
changes in iodine replete areas was found to be the key factor for normal progress of 
pregnancy and resulted in a better outcome (de Benoist et al., 2003, Glinoer, 2004).  
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It was also reported that maternal thyroid disease during pregnancy has a negative 
impact on foetal growth and offspring’s neuropsychological development 
(Cranefield, 1962, Koibuchi and Chin, 2000, Delange, 2001, Patel et al., 2011). 
Possible association between thyroid disease and iron deficiency anaemia has been 
speculated (Hess et al., 2002, Zimmermann and Köhrle, 2002). A recent study 
conducted at the LGH found that 20% of pregnant women in Northern-Tasmania had 
iron deficiency anaemia (IDA) (Khalafallah et al., 2010). Since pregnancy increases 
the demand for many nutrients including iodine and iron, a possible link between 
iron deficiency anaemia and IDD during pregnancy was supported (Kramer, 2003). 
 
It is agreed that goitre and hypothyroidism are most common in iodine deficient 
areas (Glinoer, 1997, Lazarus and Okosieme, 2000, Glinoer, 2004, Gibson, 2006, 
Vanderpump, 2010). However, clinicians only consider testing for thyroid 
dysfunction in pregnancy if one or more of the following situations occur; symptoms 
exist that suggest the condition; there is a family history of the disease; or there is the 
presence of an associated medical condition (Abalovich et al., 2002, Reid et al., 
2010). Nearly a third of women were overlooked when applying a case-finding 
approach rather than routine screening (Vaidya et al., 2007). Despite this, general 
screening for thyroid function prior or during pregnancy is not a standard practice in 
Australia generally and Tasmania in particular. Hence, the actual incidence of 
thyroid diseases and its possible complications within the pregnant population of 
Tasmania is not yet known. It is also worth mentioning that the study is specific for a 
geographical region (Tasmania) that has a persistent history of iodine 
deficiency(Hynes et al., 2004). Other studies conducted in different regions of 
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Australian were either among iodine sufficient population or among unknown iodine 
status (Gilbert et al., 2008b, Schneuer et al., 2012, Ong et al., 2014). 
 
1.2 Iodine and Iodine Deficiency Disorder (IDD) 
1.2.1 Background  
Iodine was discovered in the early 19th century by Bernard Courtois, a French 
chemist (Richards, 1995). Davy, a British chemist and Gay-Lussac of France 
however named the element “Iodine/Iod” in reference to a purple colour in Greek 
language (Kelly, 1961, Richards, 1995). Hypothyroidism as a result of goitre is 
believed to occur predominantly in regions of mountainous terrain where past 
glaciations and heavy rainfall has resulted in the leaching of soil iodine 
(Goldschmidt, 1952, Andersson et al., 2005, Zimmermann, 2010). Geographical 
isolation and largely self-sufficient food production in a moderately to severe iodine 
deficient region worsens the problem (Assey et al., 2006). Tasmania falls under such 
a category and is known to be a typical endemic goitre area (Gibson, 2006, Richards 
and Stewart, 2007).  
 
Apart from natural causes of iodine deficiency, replacing iodine-based disinfectants 
by contemporary non-iodine ones was suggested to be another reason for low-iodine 
milk production in Tasmania (Richards and Stewart, 2007). The author also proposed 
that introduction of fast food in late 20th century probably had a significant role in re-
appearance of IDD in both developed and developing countries (Richards, 1995, 
Richards and Stewart, 2007). IDD has been recognised as a public health problem 
affecting many communities globally (Andersson et al., 2012). Australia, including 
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Tasmania, was found to be mildly iodine deficient according to a nationwide study 
(Li et al., 2006). 
 
Internationally, iodine supplementation programs were first implemented in the 
1920s by the United States of America (USA) and Switzerland (Marine and Kimball, 
1920). However, this was not widely adopted until the World Health Organisation 
(WHO) launched a Universal Salt Iodisation (USI) programme in the early 1990s 
(Andersson et al., 2005). In Tasmania, it was only between the 1950s and 1960s 
when iodine tablets were dispersed to people in order to contain goitre and prevent 
IDD (Gibson, 2006).  
 
While fortifying bread with iodised salt was recommended by the Tasmanian Iodine 
Supplementation Program (TISP) launched in 2001, it was then legislated to be a 
mandatory fortification in 2006 (Richards, 1995, Burgess et al., 2007, Richards and 
Stewart, 2007). However, it is worth noting that both studies were conducted during 
voluntary fortification period. Nevertheless, mild iodine deficiency in Tasmania was 
found to be determined, concluded by Menzies Research Institute, Hobart, Tasmania 
(Hynes et al., 2004).  
 
In addition, a nine year follow up study of school-aged children who were born to 
iodine deficient mothers revealed some cognitive disorder, i.e., reading difficulties 
when compared to peers of similar age and school level (Hynes et al., 2013). This 
indicates that earlier detection and prevention of iodine deficiency disorders in future 
mothers can reduce risk of cognitive disorder in their children.  
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1.2.2 Iodine & iodine metabolism  
Recognition of iodine’s importance was related to its essential role in the production 
of thyroid hormones; thyroxin (T4) and triiodthyronin (T3). In the stomach and 
duodenum, >90% of iodine in the form of iodide was found to be  rapidly absorbed 
(Taurog, 2000, Trumbo et al., 2001). While the half life of iodine was reported to be 
10 hours in normal health and adequate nutritional conditions, it was found to be 
reduced in case of iodine deficiency (Taurog, 2000).  
 
Iodine uptake in the thyroid gland is dependent on its supply, with 10% of iodine 
uptake enough in case of iodine sufficient supply and >80% of uptake could be 
required in insufficient iodine supply (DeGroot et al., 1975). The sodium/iodide 
symporter (NIS) system was found to be responsible for iodide transfer into the 
thyroid (Eskandari et al., 1997).  
 
In the colloid, the enzyme thyroid peroxidase was established to play a crucial role in 
iodine coupling and the production of thyroid globulin (TG), T3 and T4 (Eskandari 
et al., 1997, Taurog, 2000, Hall, 2010).   Circulating T3 and T4, after reaching the 
target organs they release iodine which enter the plasma iodine pool where it is taken 
up again by the thyroid or excreted (90%) by the kidneys (Taurog, 2000), (Figure 1-
1). 
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                        Figure 1-1 Iodine metabolism and transport 
                        At the basal membrane NIS regulate transfer of iodine from the circulation 
into the thyroid   cell. The apical membrane is where the thyroid peroxidase 
enzyme helps the iodine to couple up with the thyroid globulin. 
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1.2.2.1 Iodine sources 
Iodine is commonly available in seawater, seaweeds and seafood. It mainly exists in 
the sea water in oxidised form, and in a lesser percentage it reaches the soil which is 
again drained back to the sea by the effect of rain (Goldschmidt, 1952). Thus, crops 
grown in these washed-off soils would be low in iodine concentration. Consequently, 
human and animals consuming food grown in these iodine-poor soils are likely to 
develop IDD (WHO, 2001). A study comparing iodine content in crops grown in 
iodine-deficient soil and crops grown in iodine-sufficient soil, resulted in 10 μg/kg 
and 1 mg/kg of dry weight of iodine, respectively (Assey et al., 2006). Iodine-
deficient soils are common in inland regions, mountainous areas, and places with 
frequent flooding, but can also occur in coastal regions (Vitti et al., 2003, Andersson 
et al., 2012).  
 
Since consuming large amounts of seaweed was a normal diet for people living on 
the coastal regions of Japan, remarkably high iodine intakes amounting to 50 to 80 
mg/day have been reported in this population (Zimmermann, 2009). In the mid-
1990s in the United States, the median intake of iodine from food was estimated to 
be 240 to 300μg/day for men and 190 to 210μg/day for women. Since salt iodisation 
programs have been applied by most countries including Australia, bread has been 
the major source for iodine. In addition to bread, milk was mentioned as well to be a 
good source for iodine in the USA and Europe (Pearce et al., 2004, Haldimann et al., 
2005). Other publications reported that, using iodophors milk in cleaning milk cans 
and cows teats increased the native iodine content of dairy products (Phillips, 1997, 
Richards and Statham, 2007).  
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1.2.2.2 Iodine requirements 
Definitions related to nutritional requirements were outlined by the Institute of 
Medicine (IOM) of the USA (Trumbo et al., 2001). The estimated average 
requirement (EAR) is the daily iodine intake that meets the requirement of half of the 
healthy individuals in a particular life stage (Trumbo et al., 2001). The recommended 
dietary allowance (RDA) however, was defined to be the average daily intake 
sufficient to meet the iodine requirement of 97–98% of healthy individuals in a life 
stage (Trumbo et al., 2001). The adequate intake (AI) was used if there was 
insufficient scientific evidence to calculate an EAR (Trumbo et al., 2001).  
 
Whilst these definitions were widely accepted in the US, the recommended nutrient 
intake (RNI) was adopted by WHO (Zimmermann, 2009). RNI was defined as the 
intake estimated to cover the needs of “nearly all” healthy individuals in the specified 
life stage (Trumbo et al., 2001). It has been recommended for men, non-pregnant and 
non-lactating women as the adequate daily iodine intake was 150 μg/d 
(Zimmermann, 2009).  
 
During pregnancy, increased production of maternal T4, retained iodine in foetal 
thyroid and increased renal clearance, were thought to be the main reasons for 
increased iodine demand (Glinoer, 1997). The latest and ongoing WHO’s 
recommendation for daily iodine supplementation during pregnancy and lactating has 
been reported to be 250 μg/day  (Andersson et al., 2007). While iodine 
supplementation for pregnant and breastfeeding women in Australia and the New 
Zealand in 2006 was 220 μg/d and 270 μg/d  respectively, the National Health and 
Medical Research Council (NHMRC) instead recommends that 150 μg/day of iodine 
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supplementation was safe and effective for pregnant and breastfeeding women 
(NHMRC, 2010). This relatively lower than WHO’s recommendation was further 
explained by the NHMR; avoiding any possible foetal thyroid depression.  
 
1.2.3 IDD 
This phenomenon was identified globally and defined by the World Health 
Organisation (WHO) as any illness related to a thyroid  disorder that could be 
prevented by dietary iodine supplementation (Zimmermann et al., 2000, Andersson 
et al., 2007). While severe iodine deficiency in pregnancy can result in irreversible 
brain damage to the foetus (cretinism), mild deficiency can lead to a decreased 
intelligence quotient (IQ) in school aged children (Chan and Kilby, 2000, Koibuchi 
and Chin, 2000, Delange, 2001, Burgess et al., 2007). 
 
The magnitude of IDD is at a global scale, with approximately 1.5 billion people 
affected (Hetzel, 1983, de Benoist et al., 2003, Andersson et al., 2005, Andersson et 
al., 2012). Although iodine deficiency was found to have a high prevalence in 
developing countries, about 600 million people in Europe were reported to suffer 
from a mild-to-severe level of iodine deficiency (Vitti et al., 2003). Subsequently, a 
safe, cost-effective and sustainable strategy was conducted using salt iodisation 
method to ensure adequate iodine intake in all affected areas (Andersson et al., 2005, 
Andersson et al., 2012).  
 
The iodised salt program was adopted by most countries around the globe, with an 
estimated 71% of the world’s population benefiting from this strategy (Andersson et 
al., 2012). Using Urinary Iodine Excretion (UIE) levels, recommendations were 
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made by WHO/International Council for the Control of Iodine Deficiency Disorders 
(ICCIDD): iodine replete, UIE ≥ 100 μg/L; mild iodine deficiency, UIE 50–99 μg/L; 
moderate iodine deficiency, UIE 20–49 μg/L; severe iodine deficiency, UIE 
< 20 μg/L) (Andersson et al., 2012). Although 24h UI is a better indicator, it is not 
practical to be used when conducting large scale studies (World Health Organization, 
2007). 
 
During a period of voluntary iodine fortification  in Australia, a cross-sectional study 
involving 1709 school-aged children from 88 schools comprising almost equal 
percentages of boys and girls, reported  a borderline iodine deficiency with a median 
UIE of 104 μg/L (Li et al., 2006). It was reported that children in South Australia, 
NSW and Victorian were either border line or mildly iodine deficient, with median 
UIE levels of 101 μg/L, 89 μg/L and 73.5 μg/L, respectively (Li et al., 2006). 
Queensland and Western Australian children were found iodine sufficient with 
median UIE levels at 136.5 μg/L and 142.5 μg/L, respectively.  
 
The median urinary iodine concentration (UIC) in  285 pregnant women who were 
enrolled prior to salt fortification with iodine and 517 enrolled after iodised salt use 
in most of Tasmania’s bakeries showed 76 μg/L and 83,5 μg/L, respectively, 
indicating a mild iodine deficiency according to the WHO classification (NHMRC, 
2010, Burgess et al., 2007). A follow-up study was performed that evaluated the 
mental development of school-aged children who were born to iodine deficient 
mothers (UIC <150 μg/L) in the previous study (Hynes et al., 2013). The study 
resulted in reductions of 10.0%, 7.6% and 5.7% in spelling, grammar and in English-
literacy, respectively, when compared with peers who were born to iodine sufficient 
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mothers (Hynes et al., 2004, Hynes et al., 2013). It was therefore suggested that even 
mild iodine deficiency during pregnancy could have long-term adverse affects on 
foetal cognitive functions, that had not been sufficiently were not compensated by 
the iodine sufficiency strategy that commenced in the state in 2001 (Hynes et al., 
2013).  
 
1.3 Thyroid Gland  
The thyroid is one of the largest glands in the human body, regulates metabolism and 
growth (Hall, 2010). It produces hormones; thyroxin, triiodthyronin and calcitonin. 
Circulating in a very small amounts in the body, they have specific effects on other 
organs and systems e.g. cardiovascular, neuropsychology, musculoskeletal and 
sexual (Hall, 2010).  
 
1.3.1 General anatomy and physiology 
It is located on the front of the neck, hugging the thyroid cartilage and the trachea 
from the level of fifth cervical vertebra (C5) to the first thoracic (T1), thus occupying 
the front surface of the second to fourth tracheal rings. Butterfly, H and U are the 
most common shapes of this gland, formed by two elongated side lobes and a small 
lingual (isthmus) lobe that connects the lateral lobes together. The average weight of 
the thyroid gland is 25-30g in adults, it is however may enlarge during pregnancy 
and menstruation. Its blood supply comes from the superior and inferior thyroid 
arteries and innervated by parasympathetic and sympathetic fibres from vagus nerves 
and the sympathetic trunk. Biosynthesis of the thyroid hormones take place in the 
thyroid functional unit which consists of a monolayer of epithelial cells that is filled 
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with thyro-globuline (colloid) (Marine and Kimball, 1920, Kopp, 2005, Braverman 
and Cooper, 2012). For the production of thyroid hormones, Iodine in the form of 
iodide (I-) is required, hence transported into this unit using NIS (Eskandari et al., 
1997, Hall, 2010). The thyroid, is responsible for production of a great number of 
protein enzymes, structural protein, transport protein and other substances, which 
increase general activity throughout the body (Bizhanova and Kopp, 2009).  
 
They stimulate Carbohydrates and fat metabolism as well as increases utilisation of 
vitamins (Hall, 2010). Thyroid hormones metabolic effect was demonstrated in an 
animal experiments, number and size of mitochondria increased in response to 
thyroid hormones ingestion, increases the rate of basic body metabolism up to 60-
100 percent (De La Vieja et al., 2000, Bizhanova and Kopp, 2009, Hall, 2010). The 
thyroid hormones, are also responsible for brain maturation and neuropsychological 
development (Chan and Kilby, 2000, Glinoer, 2004, de Escobar et al., 2004, Hall, 
2010, Yassa et al., 2010). Maintaining thyroid hormones and its functions within 
normal and regular secretory level, gained by a specific negative feed-back 
mechanism within the hypothalamus-pituitary-thyroid axis (Glinoer, 2004, Hall, 
2010). 
  
Secretion of thyroid hormones T4 and T3 is directly stimulated by the TSH; TSH is 
secreted from the anterior lobe of the pituitary gland and is stimulated by the 
Thyrotropine releasing hormone (THR) in the hypothalamus, hence is called 
hypothalamic-pituitary-thyroid axis (Chiamolera and Wondisford, 2009), (Figure 1-
2). 
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Figure 1-2 Mechanism of the thyroid hormones regulation. 
Thyrotropin releasing hormone (TRH) in the hypothalamus is activated by the negative feedback of 
low thyroxin (T4) and triiodthyronin (T3) in the circulation. Secretion of TRH stimulates the anterior 
lobe of the pituitary gland to produce thyroid stimulating hormone (TSH). TSH stimulates the thyroid 
gland; synthesis and secretion of T4 and T3 hormones are then compensated. 
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1.3.2 Thyroid hormones and pregnancy 
Although increased demand for energy, nutrients, minerals and vitamins is usually a 
benign physiological feature of pregnancy, biochemical values of the thyroid 
function can still be altered (Burrow, 1990, Glinoer, 1999, Glinoer, 2004). Pregnancy 
has been described as a status where dramatic hormonal changes take place that 
result in increased thyroxin binding globulin (TBG), an increase in urinary iodine 
excretion, increased activity of the placenta, decreased TSH and increased human 
chorionic gonadotropin (HCG) (Glinoer, 1999). This results in increased thyroid 
hormones, metabolism and an increased demand for iodine (Glinoer, 2004, Yassa et 
al., 2010). During the first and second trimesters, level of TBG and T4  increase 
under the effect of increased levels of estrogens and HCG, respectively (Epstein et 
al., 1994, Glinoer, 1999). Maintaining the balance between these changes and normal 
progressing of the pregnancy is achievable in iodine sufficient area, difficult in 
iodine insufficient areas (Glinoer, 2004).  
 
1.3.2.1 Role of iodine and thyroid hormones in brain development 
The relationship between the thyroid gland, severe iodine deficiency and 
neurological manifestations in human (e.g. cretinism)  was first established and 
documented in the literature (Cranefield, 1962). During foetal development, the 
thyroid gland was found to reach maturation at 11-12 weeks of gestational age 
(Obregon et al., 2007). The presence of thyroid hormones in foetal neurological 
tissues was evidenced by the detection of T4 and T3, it was suggested that T4 and T3 
play a crucial role in growth and neuropsychological development during and after 
gestation (Chan and Kilby, 2000, Koibuchi and Chin, 2000, Calvo et al., 2002, 
Kester et al., 2004, Patel et al., 2011). It was also explained earlier that myelination 
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and neuronal/glial cell differentiation is regulated initially by thyroid hormones at 
genes level (Bernal and Nunez, 1995).  
 
1.4 Thyroid diseases and pregnancy 
Goitre is one of the prominent sign of thyroid disease in iodine deplete regions 
(Andersson et al., 2007, Zimmermann, 2010). While hypothyroidism, as result of 
goitre is believed to be more common in iodine-poor regions, an autoimmune-origin 
of thyroid diseases (e.g. Grave’s disease and Hashimoto thyroiditis) were found to be 
the most common causes in iodine-replete areas (de Benoist et al., 2003, Andersson 
et al., 2007, Vanderpump, 2010).  
 
Prevalence of thyroid dysfunction can vary from as low as 0.1 % to as high as 15.5% 
(Table 1-1). It was reported by some large-scale studies that the prevalence of 
thyroid disease during pregnancy, identifying 0.3-0.5% of overt hypothyroidism 
(OH) cases and 1.5-4% of subclinical hypothyroidism (SCH) (Allan et al., 2000, 
Casey et al., 2005, Negro and Mestman, 2011). Iodine deficiency was found to play a 
negative role in thyroid function, it was emphasised that a higher percentage of 
disease to be anticipated more in iodine-deplete areas (Klein et al., 1991, Stagnaro-
Green et al., 2011). Thus, OH and SCH, are the two disorders most commonly 
encountered thyroid disorders during pregnancy in iodine poor areas and 
consequently believed to be associated with adverse effects on the development of 
the foetus and on the course of the pregnancy (Stagnaro-Green et al., 2005). 
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Table 1-1 TSH upper normal value and prevalence of thyroid dysfunction 
Source TSH Prevalence / comments 
(Hollowell et al., 2002) 4.5 4.3% SCH, 0.3% OH 
(Haddow et al., 2004) 1st trimester >5.2 
2nd trimester >4.2 
4% Hypothyroidism 
(Casey et al., 2005) >97.5th percentile 2.5% SCH, 0.2% OH 
(Vaidya et al., 2007) 4.2 1.6% SCH, 1% OH 
(Marwaha et al., 2008) 4.2  14.2% SCH, 1.3% OH 
(Gilbert et al., 2008a) 2.15 4.5% elevated TSH 
(Blatt et al., 2012) Trimester specific 15.5% tested positive for gestational hypothyroidism 
(Moreno-Reyes et al., 2013) 1st trimester 2.5-3 
2nd trimester >3 
7.2% (6.8% SCH, 0.4% OH) 
(Altomare et al., 2013) 1st trimester 2.5-3 
2nd trimester >3 
12.3% had high TSH (hypothyroidism) 
(Diéguez et al., 2016) 4.5 5.5% (1.9% OH, 3.6 %SCH) 
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As pregnancy has been reported to affect thyroid function, monitoring for thyroid 
activity using certain laboratory parameters has been proposed (Glinoer, 1999, 
Glinoer, 2004). Upon conception, hCG hormone increases which in turn stimulate 
thyrocytes (TG) to induce a transient increase in FT4 levels, which is mirrored by a 
lowering of TSH concentrations. Following this period, serum FT4 concentrations 
decrease slightly (10–15% on average), and serum TSH values steadily return to 
normal. In line with these variations, both FT4 and TSH reference intervals change 
throughout pregnancy, depending on gestational age (Vermigllo et al., 1995, Glinoer, 
2004). This is generally stabilised by the end of the second trimester when iodine 
intake was adequate (Glinoer, 2004). Thus, trimester specific TSH reference was 
highly recommended (Table 2-1). The table demonstrates variability in the intervals 
from one population to another. Therefore, developing population sample-based 
trimester-specific range for TSH is mandatory. 
 
T3/T4 ratio is another parameter found to reflect thyroid stimulation during 
pregnancy (Glinoer, 1999). The last parameter proposed for monitoring thyroid 
behaviour during pregnancy was TG, it was reported to have tendency to elevate 
more in the third trimester of pregnancy (Rasmussen et al., 1989, Glinoer, 1999). 
Although measuring FT4 using liquid chromatography/tandem mass spectrometry 
(LC/MS/MS) methods have been recommended, using trimester-specific TSH has 
been advised to consider as well (Stagnaro-Green et al., 2011). 
 
Thyroid diseases with an autoimmune association, is the most prevalent in iodine 
sufficient regions (Moreno-Reyes et al., 2013). It was reported that 10-15% of iodine 
sufficient population tested positive to thyroid peroxidase (TPO) antibodies (Glinoer 
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et al., 1994, Pop et al., 1995).  The presence of TPO antibodies have  been linked to 
pregnancy complications, postpartum thyroid dysfunction and progression to a 
symptomatic disease (Negro et al., 2011). Furthermore, the risk of spontaneous 
abortion and preterm delivery were also increased in women with auto antibodies 
(Glinoer et al., 1994). Evidence of complications related to positive thyroid 
autoimmune status of pregnant women living in iodine sufficient conditions are far 
greater than of negative TPO status. Nevertheless, testing for thyroid antibodies are 
found to be of very little clinical help because a clear relationship between these 
antibodies and recurrent pregnancy loss could not be established (Negro et al., 
2010b). 
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Table 1-2 Population-based trimester specific intervals for TSH  
 
  Trimestera 
Reference First Second Third 
1 (Haddow et al., 1999)  0.08-2.73 0.39-2.70 _ 
2 (Stricker et al., 2007)  0.09-2.83 0.20-2.79 0.31-2.90 
3 (Panesar et al., 2001)  0.03-2.30 0.03-3.10 0.13-3.50 
4 (Soldin et al., 2004)  0.24-2.99 0.46-2.95 0.43-2.78 
5 (Bocos-Terraz et al., 2009)  0.03-2.65 0.12-2.64 0.23-3.56 
6 (Marwaha et al., 2008)  0.60-5.00 0.43-5.78 0.74-5.70 
7 (Blatt et al., 2012) 0.10 - 2.50  0.55 - 2.75 0.43 - 2.91 
8 (Diéguez et al., 2016) 0.20- 4.50  _ _ 
(Gilbert et al., 2008a) 0.02–2.15 _ _ 
a TSH in mIU/L, with parenthetical data indicating 5th and 95th percentiles (1,3,6) or 2.5th and 97.5th percentiles (2,4,5,7,8) 
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1.4.1 IDD Complications in pregnancy  
Maternal, foetal and neonatal complications of untreated thyroid diseases during 
pregnancy have been well investigated (Cranefield, 1962, Davis et al., 1989, Millar 
et al., 1994, Haddow et al., 1999, Allan et al., 2000, Glinoer, 2001, Abalovich et al., 
2002, Casey et al., 2005, Casey et al., 2006, Casey and Leveno, 2006, Negro et al., 
2011, Sarkar, 2012, Männistö et al., 2013). Although complications due to thyroid 
dysfunction during pregnancy can widely be variable, some conditions such as 
(gestational diabetes, gestational hypertension, miscarriage, preterm delivery and 
foetal death) were frequent outcome (Table 3-1). 
 
1.4.1.1 Obstetric complications 
Untreated OH was demonstrated to show negative impact on pregnancy outcome as 
well as foetal neuropsychological development (Abalovich et al., 2002, Haddow et 
al., 1999). Risk of foetal loss was reported to be as high as 60% among pregnant 
women with OH (Abalovich et al., 2002). It was also found that the risk for 
gestational hypertension increases to 22% in pregnant women with OH compared to 
those without (Leung et al., 1993). It was concluded that risk of foetal death was 
found to be increased among a study population with combined OH and pregnancy 
(Allan et al., 2000). Although association between GDM and hypothyroidism have 
previously been rejected, later publication reported a positive relationship (Casey et 
al., 2007, Cleary-Goldman et al., 2008, Korevaar et al., 2013). 
 
Placental abruption and preterm delivery were demonstrated to be three times and 1.8 
times, respectively more likely in women with SCH. Preterm deliveries (<32weeks) 
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had a three-fold incidence in subclinical hypothyroidism (Casey et al., 2005, 
Stagnaro-Green et al., 2005). A recent study has shown that pregnant women with 
SCH are at significant risk of developing gestational diabetes (Negro and Stagnaro-
Green, 2014). Also, the risk of spontaneous abortion and preterm delivery were  
increased in women with auto antibodies (Glinoer et al., 1994, Glinoer, 2001).  
 
1.4.1.2 Neonatal complications 
Neonates also share risk of complications with maternal thyroid disease with the 
birth weight of children born to mothers with OH found to be decreased (Idris et al., 
2005). Although guidelines for early diagnosis and management of overt 
hypothyroidism in pregnancy has been well established, complications such as 
congenital hypothyoiridism, neuropsychological development (IQ) deficit and foetal 
death are still prevalent in some countries (Blazer et al., 2003, Chan and Kilby, 2000, 
de Escobar et al., 2004).  
 
It was suggested that untreated hypothyroidism and probable subclinical 
hypothyroidism during pregnancy was associated with a risk of a poorer outcome 
and a three-fold increased predisposition for learning difficulties (Haddow et al., 
1999). Nevertheless, a study conducted in the Netherlands failed to define any 
association between thyroid status in early pregnancy and cognitive development in 
offspring (Henrichs et al., 2010).  Hypothyroxinemia detected during the first 
trimester, irrespective to the increased TSH, associated with a higher risk of poor 
neuropsychological development of the progeny (Morreale de Escobar et al., 2000). 
In contrast, other studies could not find positive relationship between maternal 
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hypothyroxinemia and impairment of neonatal cognitive development (Oken et al., 
2009, Craig et al., 2012). 
Further studies reported that neonatal sepsis, respiratory distress syndrome (RDS), 
transient respiratory tachypnoea and apnoea were associated with  maternal thyroid 
disorders, either primary hypothyroidism or hyperthyroidism (Männistö et al., 2013). 
More recently, smaller head circumference and lower brain weight were found being 
linked to babies born to TPO positive mothers who were white/non-Hispanic (Wilson 
et al., 2014).  
 
 
24 
 
Table 1-3 Variability of maternal and neonatal complications in association with thyroid dysfunction 
Reference  Type of thyroid dysfunction Maternal complications Neonatal complications 
(Toulis et al., 2014) Subclinical hypothyroidism 
(SCH) 
Gestational diabetes (GD)  
(Korevaar et al., 2013) SCH 
Isolated hypothroxinemia 
(IH) 
Premature labour (PL) 
2.5-fold increased risk of 
premature delivery, a 3.4-fold 
increased risk of spontaneous 
premature delivery, and a 3.6-fold 
increased risk of very premature 
delivery 
 
(Mannisto et al., 2013) Subclinical 
hypothyroidism(SCH) 
Increased risk for GD, Pre-
eclampsia Preterm 
Preterm babies, sepsis, ARDS 
(Karakosta et al., 2012) SCH+Autoimmunity 4-fold increase risk for GD 3-fold increase risk for low birth 
wt. 
(Tudela et al., 2012) SCH 3-fold in GD   
(Stagnaro-Green, 2011) Overt hypothyroidism(OH) Pre-eclampsia,gestational 
hypertension(GHTN) and 
spontaneous abortion. 
cretinism, foetal death 
(van den Boogaard et al., 
2011) 
SCH Pre-eclampsia  
(Su et al., 2011) OH 
 
 
SCH 
 
 -Increased fetal loss, low birth 
weight, and congenital circulation 
system malformations. 
-Foetal distress, preterm delivery, 
poor vision development, and 
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IH 
neurodevelopment delay. 
-Foetal distress, small for 
gestational age, and 
musculoskeletal malformations. 
(De Vivo et al., 2010) SCH 
Autoimmunity 
Increased risk for miscarriage 
Increased risk for miscarriage 
 
(Ashoor et al., 2010) SCH Increased risk for miscarriage  
(Negro et al., 2010a) SCH with TPOAB Increased risk for miscarriage  
(Li et al., 2010) SCH  Impaired neuropsychological 
development 
(Benhadi et al., 2009) SCH  Foetal death 
(Vermiglio et al., 2004) IH with iodine deficiency  Impaired neurosychological 
development(attention deficit and 
hyperactivity disorder) 
(Allan et al., 2000) SCH (TSH>6.0mIU/L)  Foetal death 
(Leung et al., 1993) SCH 
Isolated 
hypothyroxinemia(IH) 
GHTN, pre-eclmpsia  
Preterm labour, GD 
 
Macrosomia 
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1.5 Iron  
Iron has been described as a component of metaloproteins that are essential for 
biochemical activities; oxygen sensing and transport, electron transfer and catalysis 
(Papanikolaou and Pantopoulos, 2005).  In the human body iron content was reported 
to vary between 3 and 5 grams, 70% of which found being utilised for heme and 
hemoglobin synthesis (Ponka et al., 1998). The liver, spleen, bone marrow, muscles, 
the kidneys and macrophages of the reticular-endothelial  system are other organs 
where iron is being utilised and stored (Bernát, 1983, Siah et al., 2006).  
 
Deoxidising the alimentary non-heme (Fe3+) iron to heme (Fe2+) form, is an essential 
process to facilitate iron absorption in the duodenum (Figure 1-3) (Pantopoulos, 
2004). Whereas there no direct mechanism for iron excretion expressed in mammals, 
the normal physiological balance of iron is maintained by dietary compensation for 
the normal loss that occurs by desquamation of epithelial cells from the gut, skin, and 
genitourinary tract (Bothwell et al., 1979).  
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Figure 1-3 Overview of iron transport and metabolism  
(A) Iron transport across duodenal epithelial cells. Reductase of the deudenal cytochrom-b (Dcytb) 
change ferric iron into ferrous iron. The divalent metal transporter (DMT1) then transport Ferrous iron 
across the apical membrane of the mature enterocyte. Iron then exported to the circulation by the 
ferroportin. This step is coupled with reoxidation of ferrous to ferric iron by membrane-bound 
hephaestin. Plasma iron is immediately scavenged by transferrin (Tf). (B) Schematic representation of 
the Tf cycle. Plasma Tf binds to its cell surface receptor (TfR) and the complex is internalized by 
endocytosis. Acidification of the endosome results in the release of ferric iron from Tf and reduction 
and subsequent transport of ferrous iron across the endosomal membrane by DMT1. The pathway is 
completed by recycling of the apoTf-TfR complex to the cell surface and release of apoTf. 
Intracellular iron is utilized for the synthesis of iron-containing proteins and the excess is stored into 
ferritin. A fraction of chelatable iron defined as “labile iron pool” (LIP) determines the cellular iron 
status (Pantopoulos, 2004) 
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1.5.1 Iron requirement 
During pregnancy the foetus stores approximately 250 mg of iron that is drawn on 
during breastfeeding (Fomon, 1993). While daily recommended requirement for 
absorbed iron is 0.55 mg per day,  breast milk supplies only 0.15 mg of absorbed iron 
per day (Fomon, 1993). During child growth 0.5 mg of iron per day is absorbed in 
excess of body losses; adequate amounts of iron during growth typically results in a 
70-kg man accumulating about 4 g of body iron (Fomon, 1993). Due to menstrual 
blood loss women generally have less iron stores than men and requirement for iron 
in a healthy childbearing-aged population estimated to be approximately 1.5-2 g per 
day (Bothwell et al., 1979, Andrews, 1999).  
 
Although iron bioavailability (absorption) is affected by diet, pregnant women during 
the second trimester are still recommended to take >50mg/d regardless of the type of 
diet.  Despite the fact that there is little evidence to support detrimental maternal or 
foetal outcomes, advocating for universal iron supplementation of pregnant women 
has been carried out in the industrialised countries (Zimmermann and Hurrell, 2007). 
A prenatal iron supplementation in iron-replete, non-anaemic low-income pregnant 
women in the USA was found to decrease incidence of preterm delivery and increase 
birth weight (Cogswell et al., 2003, Siega-Riz et al., 2006).  
 
1.5.2 Iron Deficiency Anaemia (IDA) during pregnancy 
Chlorosis or “the green sickness” was the term used in the medieval age describing 
people with pallor (Guggenheim, 1995, Kiple and Ornelas, 2001). Approximately 
24.8% of the world’s population is affected by anaemia, 30-40% of the cases were 
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pregnant women and preschool children (Benoist et al., 2008, McLean et al., 2009). 
It has been reported that 75% of anaemia in pregnancy has been identified to be of 
iron deficiency type (Benoist et al., 2008, McLean et al., 2009, Horowitz et al., 
2013). It was also reported that heavy menstruation, high parity, intrauterine devices 
and vegetarian diet were strong contributing factors on the rise of IDA (Zimmermann 
and Hurrell, 2007). In Northern Tasmania 20% of pregnant women have been 
identified to be suffering from IDA (Khalafallah et al., 2010).  
 
Pregnancy has previously been explained to be a condition when foetal growth and 
maternal blood volume expansion lead to increased nutritional demand including 
iron (Hallberg, 1995). It was established that iron requirement during pregnancy was 
equal to that contained in about 4 units of blood (about 1 kg), most of which is 
needed in the last two trimesters (Bothwell et al., 1979). 
 
 From a dietary aspect IDA was highly expected when iron requirements are greater 
than energy needs and that would be the case in infants and young children, 
adolescents, heavily menstruating women and pregnant women (Earl and Wotecki, 
1993, Zimmermann and Hurrell, 2007). It was found that women with multiple 
pregnancies were susceptible to IDA as well as their offspring when there were no 
enough intervals between pregnancies for the body to re-establish it’s iron stores 
(Kilbride et al., 1999).  
  
1.5.3 Possible complications of IDA in pregnancy  
Although there is not conclusive evidence regarding the effect of maternal IDA on 
infants, cognitive and motor development in school aged children have been shown 
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to be affected (Scholl and Hediger, 1994, Sachdev et al., 2005). IDA was found to 
increase the risk of preterm labour, low birth weight and infant mortality particularly 
during the first and second trimesters of pregnancy (Brabin et al., 2001).  
 
It was suggested that children who have IDA in infancy are at risk of delayed 
developments when compared to those with normal iron status (Lozoff et al., 1991). 
In contrast, adverse effects of iron deficiency and/or the absence of iron in the 
developing brain on neuromotor development were not conclusive (Beard, 2001). 
IDA in third trimester and its effect on child’s mental development were studied in 
China, resulted in  a significant lower mental development index (Chang et al., 
2013). Susceptibility to/and duration of infections in children, mainly of the upper 
respiratory tract  was reported to be aggravated by IDA (de Silva et al., 2003).  
 
1.5.4 IDA and thyroid disease  
The association between thyroid diseases and anaemia was first reported in the late 
19th century when post-thyroidectomised patient developed anaemia, although the 
reasons for this were unclear (BOMFORD, 1938). It was reported that 53/202 
(26.2%) of patients pre-diagnosed with hypothyroidism had anaemia (Horton et al., 
1976). Furthermore, 60/118 (50.8%) of patients who were studied more closely, were 
found to have iron level at the lower margin of the reference interval (<12 µmol/L) 
and 42 (35.5%) had a low serum concentration of iron (Horton et al., 1976).  
 
Using haemoglobin only to evaluate IDA was labeled as non-sensitive and non-
specific (Zimmermann, 2008).  Although serum ferritin was reported to be a better 
parameter in reflecting iron store, it found to be unreliable in the presence of active 
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inflammatory process. Iron saturation transferrin and erythrocyte zinc protoporphyn 
were used to determine iron-deficient erythropoiesis, but lacking accurate 
diferentiating acute IDA from anaemia of chronic illness was its back-
draw(Zimmermann, 2008). Hence, a combination of serum ferritin and serum 
transferring receptor was suggested for evaluating iron store and tissue iron 
deficiency, respectively (Zimmermann, 2008) .  
 
IDA has also been found to have a negative impact on maternal thyroid function, 
which is compounded in areas where there are nutritional deficiencies (Zimmermann 
et al., 2000). In regions of endemic goitre, thyroid response to iodine 
supplementation was impaired in children with IDA compared to iron sufficient 
children (Zimmermann et al., 2000).  In another study, the efficacy of administered 
iodised salt was improved in children suffering from goitre, by managing IDA (Hess 
et al., 2002). This is supported by another study demonstrating that combined 
supplementation with Fe and Iodine had even better effect on thyroid function than 
iodine supplementation alone (Eftekhari et al., 2006). 
 
1.6 Screening for IDD in pregnancy 
Regardless of the growing evidence of thyroid disorders and its consequences on 
pregnancy, foetal growth and neuropsychological development of children, clinicians 
have been reported to still prefer a case finding approach rather than generalised 
screening for thyroid diseases (Glinoer, 2001, Casey et al., 2005, Casey and Leveno, 
2006, Casey et al., 2006, Vaidya et al., 2007). It has been suggested that 20-50% of 
pregnant women with suspected thyroid disease would be missed when selectively 
approached for thyroid screening (Vaidya et al., 2007, Horacek et al., 2010).  
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A recommendation in favour of generalised screening for thyroid diseases during 
pregnancy was made on a joint statement by the American Thyroid Association 
(ATA), the American Association of Clinical Endocrinologists (AACE) and the 
Endocrine Society (ES) in 2005 (Gharib et al., 2005). In a subsequent meeting the 
previous statement has been changed, universal screening of thyroid diseases was not 
as effective as a selective screening approach (Stagnaro-Green et al., 2011, Garber et 
al., 2012).  
 
In contrast, some European countries have introduced universal screening for thyroid 
disease during pregnancy, an approach that has been widely accepted, particularly in 
Spain and Belgium (Vila et al., 2014). After a thorough review of the serious impact 
of undiagnosed and therefore untreated OH on the mother and foetus, and 
neurocognitive development of the unborn child, universal screening has been 
strongly suggested (Stagnaro-Green, 2012).  
 
General screening has been found to be cost effective not only when compared with 
no screening, but also when compared with screening of high-risk women (Thung et 
al., 2009, Dosiou et al., 2012). Although, the latest conjoint statement made by the 
American thyroid association don’t recommend a general screening of the thyroid 
diseases in pregnancy, disagreement and consequences of late diagnosis and/or 
untreated cases have been emphasised by others (Allan et al., 2000, Abalovich et al., 
2002, Gharib et al., 2005, Vaidya et al., 2007, Stagnaro-Green et al., 2011).  
 
 
 
33 
1.6.1  Screening tools and interpretation of results 
1.6.1.1 Screening for maternal thyroid function 
Testing for TSH, FT4, FT3 and TPO antibodies are basically required in order to 
assess thyroid function. Most biochemical tests are performed using sophisticated 
automated devices in the biochemistry sections of medical laboratories. 
Immunoassay is the most common method for measuring FT4 and FT3, reliability of 
which during pregnancy has been reported to be questionable (Lee et al., 2009). 
Chemiluminescent (immunoassay-based) can be refered to substances capable of 
yielding higher specific activities when used as direct reagent labels in this context, 
and thus provide a basis for the development of ‘ultra-sensitive’, non-competitive, 
immunoassay methodologies (Ekins et al., 1989). Enzymes catalysing 
chemiluminescent reactions or yielding fluorescent reaction products can likewise be 
used as labels yielding high effective specific activities and hence enhanced assay 
sensitivities (Ekins et al., 1989).  
 
It has been reported that the serum of pregnant women is characterized by higher 
level of TBG and nonesterified fatty acids and by lower concentrations of albumin 
compared to the serum of non-pregnant women (Stagnaro-Green et al., 2011). One of 
the most sophisticated devices is the dialysate or ultrafiltrate online solid phase 
extraction–liquid chromatography/tandem mass spectrometry (LC/MS/MS), it has 
been highly recommended for accurate measurement of FT4 (Yue et al., 2008, 
Stagnaro-Green et al., 2011). In addition, it was demonstrated that LCMSMS 
enhanced diagnostic capabilities by affording the specificity, precision, and limiting 
of quantification necessary for the reliable measurement of thyroid hormones. These 
methods were found to be especially important in states of disease and during 
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pregnancy when protein binding is a factor that interferes with other methods for 
thyroid hormone analysis (Soldin and Soldin, 2011, Hoofnagle and Roth, 2013). 
 
Regardless previous recommendation it has been reported by other authors that 
immunoassay performs well, show low results when expected and report high results 
when excess of FT4 occurs (Anckaert et al., 2010). Unavailability of LC/MS/MS 
prompts each laboratory individually estimated trimester-specific references for TSH 
has been recommended to follow instead (Stagnaro-Green et al., 2011). In case 
laboratories don’t have their own trimester-specific reference for TSH, the following 
reference ranges have been recommended to follow; first trimester, 0.1–2.5 mIU/L; 
second trimester, 0.2–3.0 mIU/L; third trimester, 0.3–3.0 mIU/L (Stagnaro-Green et 
al., 2011).  It is worth mentioning that LGH pathology (where study samples were 
processed) reports their reference range for TSH and FT4 in the general population 
as (0.47-4.70 mU/L) and (10.0-28.2 pmol/L), respectively. 
 
1.6.1.2 Screening for iodine status 
As more than 90% of ingested iodine was found to be excreted by kidneys, urinary 
iodine (UI) was thought to be the best source for iodine level evaluation (Vought and 
London, 1967). While UI 24 hour urine was described to be a better indicator, UI can 
be measured in spot urine specimens from a representative sample of the target group 
and expressed as the median, in µg/L (World Health Organization, 2007). For 
national school-based surveys of iodine nutrition, the median UI from a 
representative sample of spot urine collections from approximately 1200 children (30 
sampling clusters of 40 children each) can be used to classify a population’s iodine 
status, according to WHO (World Health Organization, 2007). 
 
 
35 
 
Although the median UI does not provide direct information on thyroid function, a 
low value suggests that a population is at higher risk of developing thyroid disorders 
(Zimmermann, 2009). It was argued that median UI’s variability from day to day 
made it an easy subject for misinterpretation (Andersen et al., 2008).  It was further 
explained that assuming subjects as iodine deficient with a spot UI of less than 100 
μg/L is not acceptable (Zimmermann, 2009). Since 24 hour urine collection was not 
practical for large scale screening also to avoid day-to-day variability in spot UI, use 
of age- and sex-adjusted (iodine:creatinine) ratio in adults was thought to be a better 
alternative (Knudsen et al., 2000). Using the following formula; urinary iodine 
(μg/L) × 0.0235 × body weight (kg) = daily iodine intake, a median UI of 100 μg/L 
corresponds roughly to an average daily intake of 150 μg. 
 
Currently, UI estimation varies according to the level of technology it is associated 
with. Thus, Urinary Iodine in this study was measured directly by ICPMS following   
dilution in an ammonium EDTA based diluent using rhodium as an internal standard 
(Agilent 7500ce Inductively Coupled Plasma Mass Spectrometer).This analysis was 
developed at the Biochemistry Department at the Royal Prince Alfred Hospital, 
Sydney. Inductively coupled plasma mass spectroscopy (ICP-MS) is an analytical 
technique that is capable of performing quantitative multi-element analysis at trace 
concentrations of these elements. An ICP-MS is capable of measuring concentrations 
to a level of ng / L of the analyte. Nevertheless, most modern techniques for testing 
UI are originally based on the old basic principles (the Sandell-Kolthof reaction) 
(World Health Organization, 2007, World Health Organization, 2013). Using the 
median urinary iodine concentration, criteria was developed by the WHO to assess 
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iodine intake in target groups. According to results of median UI (μg/L) for pregnant 
women, iodine intake was evaluated; UI < 50 μg/L would indicate to insufficient 
iodine intake (World Health Organization, 2013). While 150-249 μg/L would 
describe adequate iodine intake, 500  μg/L and more would be evaluated as excessive 
level (World Health Organization, 2013). Lactating women were categorised 
differently bearing in mind iodine excretion in milk as well as in urine; median UI < 
100 μg/L would be indicating insufficient intake and a 100 μg/L and more would be 
of adequate intake (World Health Organization, 2013).  
 
1.7 Cord blood and neonatal thyroid assessment 
Umbilical cord blood has long been endeavoured for evaluating neonatal thyroid 
status (Walfish et al., 1979, Henry et al., 2000). Maternal and neonatal 
hypothyroidism has a negative impact on the foetal neuropsychological development 
(Rovet et al., 1987, Haddow et al., 1999, Idris et al., 2005). Although a well 
correlation was reported between TSH results of the umbilical cord blood and the 
neonatal venous blood, the latter have been recommended (Walfish et al., 1979, 
Jacob and Peters, 2015). Since confirmatory venous blood TSH was required for 
elevated cord blood TSH results, recalling the patients back demonstrated to be a 
non-practical  approach (Walfish et al., 1979, Wu et al., 1999).  
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1.8  Aims and Hypothesis 
Aims: 
1. To biochemically, determine the rate of thyroid function alterations within a 
limited group of obstetric population in northern Tasmania.  
2. To determine whether altered thyroid was associated with clinical 
complication to the mothers and their babies during pregnancy and delivery. 
3.  To determine whether iron deficiency anaemia and iodine deficiency are 
associated with low thyroid status.   
4. To find out whether a general screening of thyroid diseases for pregnant 
women, identify more cases than the current routine selective screening. 
5.  To determine if cord TSH can be used as a screening tool for neonatal 
hypothyroidism.   
 
Hypotheses:  
1. The number of pregnant women with thyroid disorder can be more significant 
if biochemically screened either prior conception or at early pregnancy. 
2. Thyroid function disorder during pregnancy has a negative impact on 
maternal and foetal wellbeing. 
3. Iodine deficiency and low ferritin levels are possible predictors for the 
thyroid dysfunction. 
4. General biochemical screening for thyroid function is a better approach in 
identifying thyroid diseases during pregnancy and preventing associated 
complications.  
5. Cord blood TSH, a non-invasive tool for neonatal hypothyroidism screening.
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2 MATERIALS AND METHODS 
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2.1 Study Design 
2.1.1 Ethics 
The study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (H119759) and was conducted between 16/04/2012 and 
15/04/2014 at the Launceston General Hospital (LGH), Tasmania, Australia. 
Informed consent was obtained by all participants. 
 
2.1.2 Recruitment  
Since all pregnant women went through pathology for gestational diabetes screening, 
thinking of the pathology as a capturing point was foreseeable. Hence, potential 
participants were invited to take part in the study while they were waiting at the 
pathology for glucose tolerance test (GTT). Upon their interest and prior to consent 
for participation, all women were individually informed about the project and 
possible outcomes. Pregnant women aged 18 years and above with absence of any 
known history of thyroid disease were included in the study (Figure 2-1). The 
researcher documented personal information, demographic data, medical history and 
medication profiles. Participants with abnormal laboratory results (high TSH levels) 
were contacted, the condition explained and referred onto the endocrinologist. It is 
worth mentioning that recruitment and sample collection was happening 
simultaneously. 
 
 
 
 
 
 
 
40 
 
Figure 2-1 Study design and Recruitment flow 
First stage, at pathology reception where invitation and information sheet were handed out to all 
pregnant women presented for GTT. Second stage, inclusion/exclusion criteria were applied to the 
interested women and informed consents were obtained. Third stage, a questionnaire was filled by the 
participant and blood nurses were notified to collect the samples.  
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Data capturing sheet was derived and modified from Abalovich et al 2002 and their 
recommended approach for case finding. The data capturing sheet was instituted in 
two parts; the first part recorded physical parameters (weight and height) and visible 
signs of goitre (enlarged thyroid gland, exophthalmia and pretibial oedema) as 
assessed by the study investigator. Gestational age, expected date of delivery, and 
type of conception were also documented.  
 
Using thyroid function testing markers (TSH, FT4 and FT3) was set as a screening 
tool (predictors) for the study group. Hence, this will divide the study population into 
normal, low thyroid status (TSH>2.5mU/L) and isolated low thyroxin 
(FT4<8.9pmol/L). Likewise, cord blood samples were also collected as part of the 
study from the participants’ babies and were tested for TSH, FT4, FT3 and anti-TPO 
antibodies. In addition to that, full blood count (FBC) and iron studies (IS) were part 
of the investigations. In addition, urine samples were collected from the participants 
for measuring urinary iodine (UI) level.   
 
The second part was the questionnaire form, which was purposely designed to obtain 
specific clinical information to identify women who would have been candidates for 
thyroid testing based on history and symptoms alone. It includes past and present 
medical history, obstetrics & gynaecological history, medications, dietary history and 
symptoms of hyperthyroidism or hypothyroidism. All abnormal findings were 
documented by the investigator and discussed with the principal investigator for 
further investigations as required. This may include referral for thyroid ultrasound or 
to an endocrinologist if clinically required. Participant’s GP’s were notified with any 
abnormality and action plan.  
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Furthermore, records of maternal, foetal and neonatal complications were collected 
in order to determine the incidence rate in each group of thyroid status. Clinical 
outcomes in the study cohort are divided into two groups; antenatal (maternal/foetal) 
complications and neonatal wellbeing parameters.  
 
Ante-partum complications are defined by the presence of the following parameters:  
oligohydromnious, polyhydromnious, gestational diabetes mellitus (GDM), 
gestational hypertension (GHTN) and pre-eclampsia, infection, placenta previa, 
threatened premature labour (TPL), ante-partum haemorrhage (APH), intra-uterine 
foetal growth restriction (IUFGR) and organ anomalies, macrosomia, biliary disease 
and abdominal or pelvic surgery. Intra-partum complications are defined by the 
presence of the following: cord prolapsed, prolonged labour, instrumental delivery, 
intrapartum haemorrhage (IPH), pyrexia and hypertension (HTN). Post-partum 
complications are defined by the presence of postpartum haemorrhage (PPH) and 
wound infection. Neonatal parameters include Apgar scores, head circumference, 
resuscitation and nursery admission.  
 
Once the questionnaire was completed, participants were given a copy of the signed 
consent with two pathology forms (Antenatal) for blood and urine samples. 
Antenatal pathology forms requested collection of blood and testing for TSH, free 
thyroxin (FT4), free triiodthronine (FT3), and anti-TPO antibodies as well as urine 
sample for iodine level. IS and a FBC were also performed to test for the presence of 
concomitant IDA. A cord-blood pathology form was attached to a copy of the 
consent of each participant and placed in the participant’s medical record. 
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Participants’ medical records were also marked with a pink-coloured label in order to 
help the labour ward nursing staff identify the participants easily.  
 
2.2 Sample collection and handling 
Fasting blood (10 ml) and urine (15 ml) specimens were collected from consented 
participants during daytime working hours. Blood samples were collected into 
different tubes according to the requested test. Specimens for FBC were collected in 
purple top BD Ethylenediaminetetraacetic acid (EDTA)-Vacutainer (K2E) tubes 
(Becton Dickenson and company, Franklin Lakes, NJ, US). Blood for TSH, FT4, 
FT3, anti-TPO antibodies and IS were collected in gold top BD Vacutainer (SST II) 
tubes. Similarly, cord blood samples for TSH, FT4, FT3, and anti TPO-antibodies 
were collected in gold top BD Vacutainer (SST II) tubes. Urine samples for iodine 
measurement were collected in plain sterile containers. 
 
Blood samples for FBC were tested within 30 minutes of collection, while samples 
for TSH, FT4, FT3 and anti-TPO antibodies were centrifuged at 4000 x g for five 
minutes and one aliquot of serum were forwarded to the Biochemistry laboratory for 
routine testing for TSH, FT4, FT3, while another 2-3 aliquots are stored at -700 C. 
 
Urine samples were divided equally between two conical tubes and paired with anti-
TPO antibody samples, then stored at -700C. Approximately one hundred frozen 
samples were collected and transported to the Royal Prince Alfred (RPA) Hospital, 
Pathology, Sydney for analysis. Cool boxes with dry ice were used to keep the 
sample temperatures at -700C during interstate transportation.   
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2.3  Tests principles 
Blood samples were analysed by Sysmex XE-5000 (Sysmex Corporation - Global - 
Kobe, Japan). Test principle in this device is based on the fluorescence flow 
cytometry method. Three parameters in FBC were considered; Haemoglobin (Hb), 
Haematocrit (Hct), Mean Corpuscular Volume (MCV). Concomitantly, samples for 
TSH, FT3, FT4 and Ferritin were assayed using The VITROS Immunodiagnostic 
System (VITROS ECI, Ortho-Clinical Diagnostics, Inc. Rochester NY, U.S.A.). All 
assays on the VITROS Analyzer employ an enhanced chemiluminescence detection 
reaction. 
 
Serum iron level and transferrin were tested using an Architect C8000 (Abbott 
Laboratories. Abbott Park, Illinois, U.S.A.). Iron was determined by using the direct 
colorimetric method without deproteinisation in the human serum. Transferrin 
measurement on the other hand was based on an immunoturbidimetric procedure, 
which measures increasing sample turbidity caused by the formation of insoluble 
immune complexes. 
 
Antenatal and cord blood serum aliquots for anti-TPO antibodies along with urine 
iodine samples were processed at the RPA, Sydney. Anti-TPO antibodies were 
measured using an IMMULITE 2000 systems analyzer (SEIMENS). It is a solid-
phase, enzyme-labelled, chemiluminescent sequential immunometric assay.  
 
Iodine in urine was measured directly by Inductively Coupled Plasma Mass 
Spectroscopy (ICP-MS) after a dilution in an ammonium EDTA based diluents in a 
quantitative application using rhodium as an internal standard. ICP-MS is an 
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analytical technique that is capable of performing quantitative multi-element analysis 
at trace concentrations of these elements. An ICP-MS is capable of measuring 
concentrations to a level of ng / L of the analyte. 
 
2.4 Data collection, entry and storage 
Data was collected using three sources of information. Firstly, questionnaire-derived 
information (the modified data capturing sheet) was used to express approximately 
one hundred parameters. A mixed of Qualitative and quantitative data was coded 
from this source. The second source was the LGH Pathology test results for FBC, IS, 
TSH, FT4 and FT3. Thirteen test parameters were obtained for each participant from 
this source. The third data source was the RPA, Sydney where results for urine 
iodine, urine creatinine and anti-TPO antibodies were collected. Data were entered 
on a daily basis into a password protected electronic data sheet and saved in the 
hospital O-drive. Original paper documents (consents, questionnaire and results) 
were sorted into numeric order according to participant’s trial identification number, 
each in a separate folder and stored in locked drawers.  
 
2.5 Data analysis 
2.5.1 Methods of statistics 
The rate of complication events in the mother and baby associated with various 
predictor variables was estimated as the incidence rate ratio (IRR; 95% confidence 
intervals; P-values) using multivariate Poisson regression. The covariates were 
selected using backward stepwise regression (P-value for removal = 0.22; P-value for 
entry = 0.12). An incidence rate ratio (IRR) of 1.00 indicates that the rate in the 
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group being compared with the comparator group (e.g. low thyroids with normal 
ones) is of no difference between the two groups; an IRR greater than 1.00 means the 
group has a higher rate than the comparator group; an IRR less than 1.00 means that 
the rate is lower than in the comparator group.  
 
Variables for possible selection include for pre- and intra-natal complications: low 
thyroid status, BMI, first baby, history of prematurity or PET, gestation at 
delivery<37weeks, APH, hypertension/PET in this pregnancy, oligo- or poly-
hydramnios, sex of baby, GDM, infection, placenta previa, TPL, IUGR, macrosomia, 
abdo/pelvic surgery, FBS, MCV, Hb. For post-natal complications the same list was 
used, plus prolonged labour, intra-partum haemorrhage and mode of delivery. 
 
Where the complications were measured as a continuous variable (i.e. APGAR 
scores at 1minute and 5 minutes or head circumference), regression coefficients 
(coef; 95% confidence intervals; P-values) were estimated using multivariate general 
linear modelling: covariates were selected using backward stepwise regression. The 
covariates shown were each categorical variables, with the coefficient being the 
estimated difference found when the covariate is present. Mean and difference (95% 
confidence intervals; P-values) estimated by general linear modelling, adjusting for 
the same covariates for each complication. 
 
Where continuous covariates were evaluated for association with outcomes, z-scores 
of variables were used ({variable-meanvariable}/SDvariable), using either natural value or 
log10 transformation. Z-scores have two advantages when used in multivariate 
regression analyses: 1) the regression constant is corrected to the mean of all of the 
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continuous variables (rather than to an abstract zero for all of the included variables, 
i.e. it remains in the middle of the data rather than at the edge of the raw data range); 
and 2) each variable is corrected to a single unit of value (units of 1 standard 
deviation), so that all variable coefficients have the same scale, and the magnitude of 
the association of each variable can be compared directly, rather than having to do 
complex mental arithmetic to correct for different units of measurement and value 
ranges. 
 
In order to determine whether any symptoms or combination of symptoms elicited at 
the initial antenatal clinic visit could predict the presence of low thyroid status, the 
association between the results from the thyroid symptoms questionnaire and the 
subsequent determination of women with low thyroid status was estimated using 
multivariate Poisson regression, with variables for inclusion in the final model 
selected by backward stepwise regression. All the questions were included unless 
there was at least one positive result in both the low and normal thyroid status 
women (any zero results make interpretation of the regression coefficients extremely 
problematical). Pre-pregnancy tremor, weight loss, carpal tunnel syndrome and 
antenatal hair loss were excluded for this reason. The regression coefficients for the 
final model were then used to calculate for each woman a combined risk score (see 
Equation 1 in results section).  
 
The optimum threshold for identification of low thyroid status was then selected, 
using receiver operating curve (ROC) analysis, based on judgement of the estimated 
sensitivity and specificity. The statistical significance of the estimated ROC area 
(whether the observations may have arisen by chance) was determined by 
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comparison of the ROC area with a normally distributed randomly-generated set of 
numbers  with the same mean and standard deviation as the risk score. All analyses 
were performed using Stata MP2 versions 13.2 (StataCorp, College Station, Texas 
USA). 
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3 RESULTS 
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3.1 Description of the study population  
During the study period, approximately a total of 2200 pregnant women of Northern 
Tasmania attended the pathology for gestational diabetes screening, mainly were 
referred from the Queen Victoria antenatal clinic, LGH. The target population were 
invited, 636 (28.9%) responded and consented to take part in the study. The study 
also includes data collected from 625 babies born to the mothers recruited to this 
study as well as investigation of their cord blood. Out of 636 participants, 609 
(95.7%) were successfully screened for thyroid status. Gestational age at presentation 
and recruitment was around 26 weeks (median 26.4; inter-quartile range 25 to 27.6; 
range 12.6 to 37.7) with no difference in recruitment age distribution between the 
normal and low thyroid status groups (P > 0.90), (Figure 3-1). 
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          Figure 3-1 Study populations with response rate and recruitment 
                 Response rate was 29% of 2200 pregnant women approached with invitation. 
Biochemical thyroid screening was processed to 95.7% of the participants and 
67% of their babies cord blood. Low thyroid status was found in 3.4% of the 
pregnant cohort. 
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Using thyroid function testing markers (TSH, FT4 and FT3) as a screening tool, the 
study population was divided into three main categories; low thyroid status (TSH > 
3mU/L and TSH >2.5mU/L), isolated low free thyroxin level (FT4 < 8.9pmol/L) and 
normal (comparator group). Among consented participants, 397 (63.1%) are 
multiparous (have previously been pregnant) and 232 (36.88%) are nulliparous (first 
time pregnant) with a median age of 29 years. The median age of gestation at 
recruitment was 26 weeks and gestational age at delivery was 39.4 weeks (Figure 3-
2). 
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                       Figure 3-2 Distribution of gestational age in study population 
                             Most participants were recruited when they were between 24 and 28   
weeks of gestational age.  
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The study data also shows that 612 (96.2%) reported being conceived naturally. The 
breakdown of ethnic background was 503 (79%), 27 (4.24%), 11 (1.7%) and 4 
(0.7%) representing Caucasian, Asian, indigenous Australian and African, 
respectively. No ethnic background was provided for 87 (13.7%) participants. 
 
Data of sub-population of 625 babies’ shows that 615 (97.9%) were born alive with 
male to female ratio of 1:1.04 (49% and 51% respectively). The total number of 
clinically observed complications for this study group is 269; 9 events (3.3%) are 
distributed in the group of low thyroid status, 135 (50.2%) events are distributed 
among the group category with low FT4 and 125 (46.5%) events of complications 
are distributed variably in the group of cohorts who have normal thyroid function. 
 
3.2 Study outcomes 
3.2.1 Incidence of thyroid abnormalities in the study population 
Thyroid function screening results for its 609 pregnant women (Table 3.1) shows 22 
(3.4%) with low thyroid function (9 with TSH > 3 mU/L and 13 with TSH 2.5-3 
mU/L), 75 (12.3%) with free thyroxin level (FT4) < 8.9 pmol/L and 272 (44%) with 
results within the normal ranges for thyroid function. Table 3-1 shows the rate of all 
recorded complications in each of these groups.  
Additionally, results of thyroid peroxidase (TPO) antibodies showed 39/585(6.3%) 
TPO-positive and 546/585 (93.3%) were negative. The average of TSH results was 
1.2 mU/L in the TPO+ve group, not much different from 1.3 mU/L in the TPO-ve 
group. 
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Table 3-1 Ante-, intra- or post-natal complications in groups defined by thyroid status  
 Total 
events 
P-
value1 
Normal 
(N=272) 
FT4 (8.9-15)  
(N=240) 
FT4(<8.9) 
(N=75) 
TSH2(2.5-
3.0) 
(N=13) 
TSH2(>3.0) 
(N=9) 
   n (%) n (%) n (%) n (%) n (%) 
Antepartum complications           
Oligohydroamnios 14 >0.90 7 (2.6%) 4 (1.7%) 3 (4.0%) 0 (0.0%) 0 (0.0%) 
Polyhydromnios 5 >0.90 3 (1.1%) 0 (0.0%) 2 (2.7%) 0 (0.0%) 0 (0.0%) 
GDM 49 0.70 23 (8.5%) 15 (6.3%) 9 (12.0%) 1 (7.7%) 1 (11.1%) 
GHT/PET 38 0.39 22 (8.1%) 10 (4.2%) 6 (8.0%) 0 (0.0%) 0 (0.0%) 
Infection 7 >0.90 3 (1.1%) 3 (1.3%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
Placenta previa 5 0.17 1 (0.4%) 2 (0.8%) 1 (1.3%) 1 (7.7%) 0 (0.0%) 
TPL 35 >0.90 18 (6.6%) 14 (5.8%) 2 (2.7%) 0 (0.0%) 1 (11.1%) 
APH 9 >0.90 2 (0.7%) 7 (2.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
IUGR/organ   
malformation 
16 >0.90 7 (2.6%) 8 (3.3%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
Macrosomia 8 >0.90 2 (0.7%) 4 (1.7%) 2 (2.7%) 0 (0.0%) 0 (0.0%) 
Biliary disease 6 0.20 4 (1.5%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (11.1%) 
Surgery 4 >0.90 3 (1.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Intrapartum complications           
Cord prolapse 0 0.036 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Prolonged labour 8  0 (0.0%) 5 (2.1%) 2 (2.7%) 0 (0.0%) 1 (11.1%) 
Forceps 7 0.010 3 (1.1%) 4 (1.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
IPH 4 0.74 1 (0.4%) 1 (0.4%) 1 (1.3%) 1 (7.7%) 0 (0.0%) 
Pyrexia 5 0.17 3 (1.1%) 0 (0.0%) 2 (2.7%) 0 (0.0%) 0 (0.0%) 
HTN 9 >0.90 5 (1.8%) 3 (1.3%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
Postpartum complications           
PPH 35 0.66 15 (5.5%) 13 (5.4%) 5 (6.7%) 1 (7.7%) 1 (11.1%) 
Wound infection 5 0.62 3 (1.1%) 1 (0.4%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
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1 P-value estimated using Fischer’s exact test  
2 Estimate of proportion of cases in sample with elevated TSH results: 3.4% (95%CI 2.1% to 5.2%) 
Abbreviations: GDM Gestational diabetes; GHT/PET Gestational hypertension/Pre-eclamptic toxaemia; TPL Threatened premature labour; APH 
Ante-partum haemorrhage; IUGR Intra-uterine growth retardation;  Surgery Abdominal or pelvic surgery; Forceps Any instrumental delivery 
(e.g. forceps or Ventouse); IPH Intrapartum haemorrhage; HTN Hypertension; PPH Postpartum haemorrhage
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3.2.2 Association of maternal and foetal complications rate with thyroid status 
Table 3-1 shows the total number of all complications during three consecutive 
periods of pregnancy/labour and distribution rate of these complications among 
different thyroid status groups. Results in Table 3-2 summarise rates and associations 
of complications in the low thyroid status group. Because of the relatively low 
number in the result group (22 with low thyroid status), as well as the limited events 
of complications, it was difficult to clearly identify any small to moderate increase in 
their rate of incidence.  
 
Results of the statistical analysis presented in tables 3-1 and 3-2 don’t show any 
significant association between ante-natal complications and low thyroid status. 
Although GDM results in Table 3-2 affecting 2 out of 22 of the same group (IRR 
1.69; 95% CI 0.55-5.25; P= 0.36) doesn’t reflect a possible association with low 
thyroid status, covariates including BMI, log.fasting blood sugar and history of PET 
demonstrate significant relationship. While the former two show predictive values 
with (IRR 2.20; 95%CI 1.73 to 2.81; P < 0.001) and (IRR 1.25; 95%CI 1.00 to 1.55; 
P= 0.46), respectively, the latter shows protective values (IRR 0.63; 95%CI 0.41 to 
0.96; P= 0.032).  
 
Other associations between individual complications and different covariates are 
demonstrated in table 3-2; macrosomia is assumed to be affected more with other 
factors than with low thyroid status. Log.fasting blood sugar, BMI, maternal age, 
gravid>2 and gestational diabetes, show positive association with a great incidence 
increase in the last two with (IRR 13.4; 95%CI 2.34 to 76.6; P= 0.004) and (IRR 
8.28; 95%CI 2.44 to 28.0; P= 0.001), respectively. While a positive association is 
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found between PET/Gestational hypertension and (log.haemoglobin, BMI and 
maternal age), history of PET, MCV and gravida >2 are negatively associated. Also, 
threatened premature labour is assumed predictable by increased history of 
prematurity (IRR 3.69; 95%CI 1.81 to 7.51; P < 0.001) and assumed protected by 
less history of PET (IRR 0.61; 95%CI 0.42 to 0.91; P= 0.014).  
 
Although results couldn’t clearly identify any significant association of GDM with 
low thyroid, it was positively associated with ante-partum haemorrhage (IRR13.9; 
95%CI 4.79 to 213; P < 0.001). Table 3-3 reflects a possible association between 
prolonged labour (PL) and low thyroid status (IRR 3.31; 95% CI 1.13 to 9.69; P= 
0.029). While there are no other intra-natal complications associated with low 
thyroid status, maternal age and log.ferritin were found positively associated with 
prolonged labour with 90% and 53% of incidence increase, respectively.  
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Table 3-2 Association of individual antenatal complications and low thyroid status 
Gestational diabetes Present (%) Absent IRR 95%CI P-value 
Low Thyroid 2 (9.1%) 20 1.69 (0.55 to 5.25) 0.36 
Normal 47 (8.0%) 540 1.00   
Covariates2       
Log. Fasting Blood Sugar3    2.20 (1.73 to 2.81) <0.001 
History of PET    0.63 (0.41 to 0.96) 0.032 
BMI3    1.25 (1.00 to 1.55) 0.046 
Macrosomia Present (%) Absent IRR 95%CI P-value 
Low Thyroid 0 (0.0%) 22 0.00 (0.00 to 0.00) 0.00 
Normal 8 (1.4%) 579 1.00   
Covariates2       
MCV3    1.71 (0.94 to 3.10) 0.08 
Log. Fasting Blood Sugar3    2.12 (1.30 to 3.47) 0.003 
History of PET    4.73 (0.70 to 32.1) 0.11 
BMI3    2.12 (1.40 to 3.21) <0.001 
Maternal age3    1.92 (1.14 to 3.22) 0.013 
Gravida 1    1.00   
Gravida>2    13.4 (2.34 to 76.6) 0.004 
Gestational diabetes    8.28 (2.44 to 28.0) 0.001 
Infection Present (%) Absent IRR 95%CI P-value 
Low Thyroid 0 (0.0%) 22 0.00 (0.00 to 0.00) <0.001 
Normal 7 (1.2%) 580 1.00   
Covariates2       
History of Prematurity    3.42 (0.62 to 18.8) 0.16 
Log. Ferritin3    1.40 (1.06 to 1.85) 0.017 
IUGR/Organ malformation Present (%) Absent IRR 95%CI P-value 
Low Thyroid 0 (0.0%) 22 0.00 (0.00 to 0.00) <0.001 
Normal 16 (2.7%) 571 1.00   
Covariates2       
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BMI3    0.69 (0.40 to 1.21) 0.19 
 
PET / Gestational hypertension Present (%) Absent IRR 95%CI P-value 
Low Thyroid 0 (0.0%) 22 0.00 (0.00 to 0.00) <0.001 
Normal 38 (6.5%) 549 1.00   
Covariates2       
Log. Haemoglobin3    1.44 (1.10 to 1.88) 0.008 
MCV3    0.70 (0.54 to 0.90) 0.005 
Gravida 2    0.51 (0.26 to 1.00) 0.05 
Gravida>2    0.30 (0.14 to 0.66) 0.003 
History of Prematurity    1.90 (0.91 to 3.97) 0.09 
History of PET    0.30 (0.17 to 0.52) <0.001 
BMI3    1.59 (1.24 to 2.03) <0.001 
Maternal age3    1.41 (1.07 to 1.85) 0.013 
Threatened premature labour Present (%) Absent IRR 95%CI P-value 
Low Thyroid 1 (4.5%) 21 0.58 (0.14 to 2.44) 0.46 
Normal 34 (5.8%) 553 1.00   
Covariates2       
MCV3    1.20 (0.90 to 1.60) 0.21 
Log. Ferritin3    1.18 (0.93 to 1.49) 0.17 
History of Prematurity    3.69 (1.81 to 7.51) <0.001 
History of PET    2.72 (0.68 to 10.9) 0.16 
Maternal age3    0.61 (0.42 to 0.91) 0.014 
Gravida 2    2.14 (0.96 to 4.77) 0.06 
Gravida>2    1.88 (0.71 to 4.95) 0.20 
Antepartum haemorrhage Present (%) Absent IRR 95%CI P-value 
Low Thyroid 0 (0.0%) 22 0.00 (0.00 to 0.00) <0.001 
Normal 9 (1.5%) 578 1.00   
Covariates2       
Log. Fasting Blood Sugar3    0.45 (0.23 to 0.87) 0.02 
History of Prematurity    Large (Large to Large) <0.001 
BMI3    0.31 (0.11 to 0.89) 0.03 
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Maternal age3    1.64 (0.99 to 2.71) 0.05 
Gravida 2    10.7 (0.84 to 135) 0.07 
Gravida>2    5.15 (0.57 to 46.8) 0.15 
Gestational diabetes    31.9 (4.79 to 213) <0.001 
1       Low thyroid status defined as TSH>2.5 
2       Incidence rate ratio (IRR; 95% confidence intervals; P-values) estimated using multivariate Poisson regression: covariates were selected using  
         backward stepwise regression, retained when P<0.22)     
3      Continuous covariates used z-scores of variables ({variable-meanvariable}/SDvariable), using either natural value or log10 transformation
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Table 3-3 Association of individual intra-natal complications and low thyroid status1 
Prolonged labour Present (%) Absent IRR2 95%CI P-value 
Low Thyroid 1 (4.8%) 21 3.31 (1.13 to 9.69) 0.029 
Normal 7 (1.2%) 580 1.00   
Covariates2       
Log. Ferritin3    1.53 (1.08 to 2.19) 0.018 
Maternal age3    1.90 (1.04 to 3.47) 0.036 
 
1 Low thyroid status defined as TSH>2.5 
2 Incidence rate ratio (IRR; 95% confidence intervals; P-values) estimated using multivariate Poisson regression: covariates were selected 
using backward stepwise regression, retained when P<0.22) 
3 Continuous covariates used z-scores of variables ({variable-meanvariable}/SDvariable) , using either natural value or log10 transformation
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Despite the fact that symptoms of thyroid disease are non-specific, the predictive 
association between possible symptoms of thyroid disease at clinic visit and the 
discovery of low thyroid function biochemically was also investigated, Table 3-4. 
Palpitation (pre-pregnancy) was positively associated with low thyroid status as well 
as with normal thyroid function; 5 (22.7%), 73 (12.6%), respectively (IRR 2.78; 95% 
CI 1.00 to 7.70; P= 0.05). Dizziness (pre-pregnancy) also shows association with low 
thyroid group 10 (45%) and 189 (32%) in the normal group (IRR 2.15; 95% CI 0.88 
to 5.23; P= 0.09). there were no other statistically significant associations. 
 
A combined risk score for low thyroid status was created from the coefficients of this 
analysis using Equation 1 (the coefficient values are the natural logs of the IRRs 
from Table 3-4): 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = −2.8676 + (𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑅𝑅𝑃𝑃𝑃𝑃 ∗ 1.0215) + (𝐷𝐷𝑅𝑅𝐷𝐷𝐷𝐷𝐷𝐷𝑃𝑃𝑃𝑃 ∗ 0.7647)+ (𝐷𝐷𝐷𝐷𝑅𝑅𝑃𝑃𝐷𝐷𝑠𝑠𝐷𝐷 ∗ −0.492) + (𝐼𝐼𝑠𝑠𝑠𝑠𝑅𝑅𝐼𝐼𝑃𝑃𝐼𝐼𝑃𝑃𝑠𝑠𝐷𝐷𝑠𝑠𝐷𝐷 ∗ −1.3638)+ (𝐷𝐷𝑅𝑅𝑃𝑃𝑠𝑠𝑠𝑠ℎ𝑠𝑠𝑠𝑠𝑃𝑃𝐷𝐷𝑠𝑠𝐷𝐷 ∗ −0.7612) 
This risk score had a range of values as shown in Figure 3-3.  A threshold for 
prediction of the presence of low thyroid status was investigated using receiver 
operating characteristic (ROC) analysis, which suggested an optimum threshold 
value of -3.25 and above for this risk score. Comparison of the ROC area with the 
random null hypothesis showed a ROC area of 0.744 (95%CI 0.636 to 0.852; 
Chi2=8.05; P=0.005). Using this value (-3.25), 15 of 22 (sensitivity or true positive 
68.2%; 95%CI 45.1% to 86.1%) patients with low thyroid status were identified as 
possible cases whilst 164 of 580 (1-specificity or false positive 28.3%; 95%CI 24.6% 
to 32.1%) patients with normal thyroid status were identified as possible cases (IRR 
5.15; 95%CI 2.13 to 12.4; P < 0.001).  
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However, relatively large numbers of patients with low and normal thyroid status had 
risk scores close to the threshold of -3.25, and minor changes to the threshold chosen 
appeared to produce large alterations in the sensitivity and specificity estimates for 
the risk score. 
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Table 3-4 The predictive association between symptoms of possible thyroid disease at clinic visit and the discovery of low thyroid 
function1 
 Low thyroid Normal thyroid    
Variable N (% of 22) N (% of 580) IRR2 95%CI P-value 
Variables included in prediction model    
Palpitations PP 5 (22.7%) 73 (12.6%) 2.78 (1.00 to 7.70) 0.05 
Dizzy PP 10 (45.5%) 189 (32.6%) 2.15 (0.88 to 5.23) 0.09 
Irritable Now 3 (13.6%) 183 (31.6%) 0.26 (0.08 to 0.84) 0.024 
Dyspnoea Now 9 (40.9%) 328 (56.6%) 0.59 (0.26 to 1.31) 0.19 
Diarrhoea Now 9 (40.9%) 348 (60.0%) 0.47 (0.21 to 1.05) 0.06 
Variables not included in model: Each IRR is variable effect when combined with the above model 
Tired PP 6 (27.3%) 125 (21.6%) 1.42 (0.49 to 4.16) 0.52 
Tired Now 13 (59.1%) 404 (69.7%) 0.98 (0.42 to 2.27) >0.90 
Constipation PP 2 (9.1%) 31 (5.3%) 1.26 (0.33 to 4.75) 0.74 
Constipation Now 8 (36.4%) 194 (33.4%) 1.00 (0.44 to 2.26) 0.99 
Heat intolerance PP 3 (13.6%) 72 (12.4%) 1.22 (0.36 to 4.14) 0.75 
Heat intolerance Now 11 (50.0%) 256 (44.1%) 1.35 (0.62 to 2.93) 0.45 
Cold intolerance PP 8 (36.4%) 197 (34.0%) 1.05 (0.46 to 2.41) 0.90 
Cold intolerance Now 3 (13.6%) 135 (23.3%) 0.56 (0.17 to 1.87) 0.35 
Insomnia PP 4 (18.2%) 135 (23.3%) 0.75 (0.25 to 2.25) 0.60 
Insomnia Now 8 (36.4%) 221 (38.1%) 0.99 (0.40 to 2.47) >0.90 
Hair loss PP 1 (4.5%) 68 (11.7%) 0.31 (0.04 to 2.48) 0.27 
Leg cramps PP 3 (13.6%) 80 (13.8%) 0.83 (0.23 to 2.97) 0.78 
Leg cramps Now 12 (54.5%) 295 (50.9%) 1.32 (0.55 to 3.16) 0.54 
Carpal tunnel syndrome Now 3 (13.6%) 80 (13.8%) 1.21 (0.33 to 4.37) 0.77 
Palpitations Now 6 (27.3%) 172 (29.7%) 0.67 (0.29 to 1.56) 0.35 
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Arrhythmias PP 2 (9.1%) 46 (7.9%) 0.89 (0.21 to 3.77) 0.88 
Arrhythmias Now 2 (9.1%) 53 (9.1%) 0.93 (0.24 to 3.70) 0.92 
Dyspnoea PP 2 (9.1%) 55 (9.5%) 0.89 (0.17 to 4.66) 0.89 
Irritable PP3 5 (22.7%) 135 (23.3%) 2.47 (0.94 to 6.50) 0.07 
Nausea & vomiting PP 2 (9.1%) 16 (2.8%) 1.93 (0.47 to 8.01) 0.36 
Nausea & vomiting Now 10 (45.5%) 273 (47.1%) 1.11 (0.48 to 2.52) 0.81 
Diarrhoea PP 13 (59.1%) 400 (69.0%) 1.58 (0.55 to 4.48) 0.39 
Weight gain PP 1 (4.5%) 54 (9.3%) 0.59 (0.08 to 4.19) 0.60 
Weight gain Now 2 (9.1%) 44 (7.6%) 1.32 (0.34 to 5.16) 0.69 
Weight loss Now 1 (4.5%) 22 (3.8%) 0.82 (0.08 to 8.37) 0.87 
Depression PP 7 (31.8%) 211 (36.4%) 0.97 (0.38 to 2.49) >0.90 
Depression Now 3 (13.6%) 80 (13.8%) 1.44 (0.41 to 5.12) 0.57 
Tremor Now 1 (4.5%) 38 (6.6%) 0.62 (0.08 to 4.83) 0.65 
Headache PP 13 (59.1%) 272 (46.9%) 1.61 (0.67 to 3.88) 0.29 
Headache Now 10 (45.5%) 313 (54.0%) 0.86 (0.37 to 2.03) 0.73 
Dizzy Now 12 (54.5%) 310 (53.4%) 1.00 (0.37 to 2.66) >0.90 
 
1 Low thyroid function defined as TSH<2.5. 
2 Association between predictive variables and low thyroid function, expressed as incidence rate ratio (IRR; 95% confidence intervals; P-values), 
estimated by Poisson regression; variables to be included in the final model were selected by backward stepwise regression from the list of 
variables shown in the table (PP=symptoms present pre-pregnancy; Now= symptoms present at the clinic visit). 
3 The variable Irritable PP was excluded from the final model: the prevalence in the two groups was similar, and the apparent possible association 
(IRR 2.47; P=0.07) was judged to be a statistical quirk. Inclusion of the variable in ROC analysis made little difference to the final results. 
Abbreviations: PP (pre-pregnancy), Now (during pregnancy) 
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Figure 3-3 Distribution of predictive risk score in patients with low or normal 
thyroid status 
Relatively large numbers of patients with low and normal thyroid status had risk scores close to 
the threshold of -3.25, and minor changes to the threshold chosen appeared to produce large 
alterations in the sensitivity and specificity estimates for the risk score. 
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3.2.3 Association of rates of neonatal complications with thyroid status 
Apgar scores, head circumference, resuscitation and nursery admission were the 
parameters defining outcomes of neonates born to mothers with different thyroid 
status. Mean Apgar scores at 1 minute of 8.69 (SD 1.08; 95% CI -0.11 to 0.82; P= 
0.14) and at 5 minutes value of 9.39 (SD 1.08; 95% CI -0.22 to 0.43; P= 0.52) in the 
low thyroid group are similar to the normal group (Table 3-5). Similarly, newborns’ 
head circumference in table 3-6 show results with a mean value of 32.3 (SD 1.41; 
95% CI -0.60 to 0.58; P > 0.90) among babies born to mothers with low thyroid, as 
well as the normal ones. These values do not demonstrate any association between 
babies head circumference and the thyroid status of the mothers. Likewise, the 
requirement for resuscitation and nursery admission to the babies (Tables 3-7, and 3-
8) do not show an association with their mothers’ thyroid condition. 
 
Apart from the statistically insignificant association between the requirement of 
resuscitations and low thyroid status, other predictors show positive association 
(table 3-8) including delivery < 37 weeks, IUGR, IPH and placenta previa.  Nursery 
admission also was associated positively with other predictors such as delivery < 37 
weeks, GHT/PET, GDM, infection, IUGR and LSCS.    
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Table 3-5 Apgar scores at 1 and 5 minutes born to mothers with low or normal thyroid status 
 n<8 (%) n 8+ Mean 
Apgar 
(SD) Coef.2 95%CI P-value 
Apgar at 1 minute         
Low Thyroid1 3 (13.6%) 19 8.69 (1.08) 0.35 (-0.11 to 0.82) 0.14 
Normal 98 (16.7%) 489 8.34 (2.23)    
Covariates2         
Delivery<37weeks      -0.56 (-1.11 to 0.00) 0.050 
Male baby      -0.21 (-0.49 to 0.07) 0.14 
IPH      -1.21 (-2.17 to -0.25) 0.014 
Apgar at 5 minutes         
Low Thyroid1 1 (4.5%) 21 9.39 (1.08) 0.11 (-0.22 to 0.43) 0.52 
Normal 31 (5.3%) 556 9.28 (2.23)    
Covariates         
Delivery<37weeks      -0.66 (-1.14 to -0.18) 0.007 
Male baby      -0.25 (-0.47 to -0.04) 0.019 
IPH      -0.37 (-0.95 to 0.21) 0.21 
LSCS      0.24 (0.03 to 0.44) 0.023 
 
1 Low thyroid status defined as TSH>2.5; numbers shown are those with Apgar scores < 8 or 8-10 
2 Regression coefficient (the estimated difference found when the covariate is present )(coef.; 95% confidence intervals; P-values) estimated 
using multivariate general linear modelling: covariates were selected (low thyroid status, BMI, first baby, history of prematurity or PET, 
gestation at delivery<37weeks, APH, hypertension/PET in this pregnancy, oligo- or poly-hydramnios, sex of baby, GDM, infection, 
placenta previa, TPL, IUGR, macrosomia, abdo/pelvic surgery, FBS, MCV, Hb) using backward stepwise regression, retained when 
P<0.22); the covariates shown were each categorical variables 
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Table 3-6  Head circumference of babies born to low thyroid status mothers or normal mothers 
 Mean (SD) Coef.2 95%CI P-value 
Low Thyroid1 32.3 (1.41) -0.01 (-0.60 to 0.58) >0.90 
Normal 32.3 (1.69)    
Covariates      
BMI3   0.28 (0.15 to 0.40) <0.001 
APH   -1.68 (-2.54 to -0.81) <0.001 
Oligohydroamnios   0.72 (-0.11 to 1.55) 0.09 
Male baby   0.34 (0.10 to 0.58) 0.006 
GDM   -0.47 (-0.98 to 0.04) 0.07 
Infection   -1.08 (-1.93 to -0.23) 0.013 
Macrosomia   1.89 (0.91 to 2.86) <0.001 
Abdo/pelvic surgery   -1.89 (-3.20 to -0.58) 0.005 
Delivery<37weeks   2.24 (1.59 to 2.90) <0.001 
 
1 Low thyroid status defined as TSH>2.5; numbers shown are those with Apgar scores < 8 or 8-10 
2 Regression coefficient (coef.; 95% confidence intervals; P-values) estimated using multivariate general linear modelling: covariates 
were selected (low thyroid status, BMI, first baby, history of prematurity or PET, gestation at delivery<37weeks, APH, 
hypertension/PET in this pregnancy, oligo- or poly-hydramnios, sex of baby, GDM, infection, placenta previa, TPL, IUGR, 
macrosomia, abdo/pelvic surgery, FBS, MCV, Hb) using backward stepwise regression, retained when P<0.22); the covariates 
shown were each categorical variables, with the coefficient being the estimated difference found when the covariate is present 
3 Continuous covariates used z-scores of variables ({variable-meanvariable}/SDvariable), using either natural value or log10 transformation 
        Abbreviations: APH Antepartum haemorrhage; GDM Gestational diabetes 
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Table 3-7 Requirement for resuscitation of babies born to low thyroid status mothers or normal mothers 
 Required (%) None IRR2 95%CI P-value 
Low Thyroid1 3 (13.6%) 19 0.78 (0.31 to 1.94) 0.59 
Normal 95 (16.2%) 492 1.00   
Covariates       
BMI3    1.13 (0.95 to 1.35) 0.16 
Placenta Previa    6.26 (3.38 to 11.60) <0.001 
GHT/PET    1.69 (0.99 to 2.88) 0.05 
TPL    1.50 (0.93 to 2.43) 0.10 
IUGR    2.36 (1.17 to 4.73) 0.016 
Prolonged labour    2.08 (0.67 to 6.43) 0.21 
IPH    2.32 (1.50 to 3.60) <0.001 
Gravida 1    1.44 (1.00 to 2.07) 0.05 
Delivery<37weeks    2.69 (1.81 to 3.98) <0.001 
 
1 Low thyroid status defined as TSH>2.5 
2 Incidence rate ratio (IRR; 95% confidence intervals; P-values) estimated using multivariate Poisson regression: covariates 
were selected using backward stepwise regression, retained when P<0.22) 
3 Continuous covariates used z-scores of variables ({variable-meanvariable}/SDvariable), using either natural value or log10 transformation 
        Abbreviations: GHT/PET Gestational hypertension/Pre-eclamptic toxaemia; TPL Threatened premature labour; IUGR 
Intra-uterine growth retardation; IPH Intrapartum haemorrhage 
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Table 3-8 Requirement for nursery admission of babies born to low thyroid status mothers or normal mothers 
 Nursery (%) None IRR2 95%CI P-value 
Low Thyroid1 1 (4.5%) 21 0.38 (0.12 to 1.24) 0.11 
Normal 58 (9.9%) 529 1.00   
Covariates       
BMI3    1.04 (0.78 to 1.38) 0.81 
History of Prematurity    0.94 (0.54 to 1.65) 0.83 
History of PET    1.99 (0.90 to 4.36) 0.09 
GHT/PET    3.71 (1.78 to 7.71) <0.001 
GDM    2.00 (1.18 to 3.38) 0.010 
Infection    3.50 (1.14 to 10.8) 0.029 
Placenta previa    3.24 (1.56 to 6.73) 0.002 
TPL    1.84 (1.04 to 3.25) 0.035 
IUGR/organ    3.69 (1.87 to 7.25) <0.001 
Surgery    3.23 (1.16 to 9.04) 0.025 
MCV3    1.74 (1.31 to 2.31) <0.001 
Delivery<37weeks    6.51 (4.08 to 10.4) <0.001 
LSCS    2.04 (1.31 to 3.18) 0.002 
 
1 Low thyroid status defined as TSH>2.5 
2 Incidence rate ratio (IRR; 95% confidence intervals; P-values) estimated using multivariate Poisson regression: covariates were 
selected using backward stepwise regression, retained when P<0.22) 
3 Continuous covariates used z-scores of variables ({variable-meanvariable}/SDvariable), using either natural value or log10 transformation 
Abbreviations: GHT/PET Gestational hypertension/Pre-eclamptic toxaemia; GDM Gestational diabetes; TPL Threatened 
premature labour;   IUGR Intra-uterine growth retardation; IPH Intrapartum haemorrhage; LSCS Lower segment Caesarean 
section
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3.3 Other considerations 
3.3.1 Association between low thyroid status and iron deficiency anaemia 
Ferritn level (body iron reserve) in the study cohort was used to define Iron 
Deficiency Anaemia. Results show that 193 pregnant women out of 590 (32.7%) 
have iron store level below 10mg/l. Although these results do not demonstrate 
association between ferritin level and thyroid status, data in (Table 3-9) clearly 
define the presence of macrocytic anaemia in 5 out of 22 participants whose TSH 
screening revealed low thyroid status.  
 
3.3.2 Examination of surveillance of thyroid function using urinary iodine 
Urinary Iodine is another proposed predictor in this study. We were able to 
successfully screen 587 participants, all under similar conditions (time and place).  
Calculation of the median urinary iodine concentration resulted in 117 µg/L. 
However, an adequate iodine intake for pregnant women is best achieved when 
median UIC is between 150-249 µg/L levels according to the latest recommendation 
by WHO (World Health Organization, 2013). Thus, the result of 117µg/L still 
reflects inadequate iodine intake for our pregnant women. Furthermore, 27/241 
(11.2%) iodine deficient participants developed isolated hypothyroxinemia during 
pregnancy. Additionally, results of median UIC was correlated with results of urine 
creatinine of the same cohort. Although r (592) =0.44 reflects almost a large positive 
effect, relevant p-value of (p=3.1) however indicates statistically a non-significant 
correlation. 
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In order to find a possible association between (UIC and TSH) and (UIC and FT4), 
correlation and regression formulas were used. Data analysis revealed very little 
effect with no statistical significance r (588) = 0.017, p=0.67 and r (588) = 0.022, 
p=0.55 for (UIC and TSH) and (UIC and FT4), respectively. 
 
3.3.3 Study results-based reference group 
TSH results (irrespective to TPO status) in the study group have been re-calculated, 
they fall between the range of 0.16 mU/L (95% CI 0.75, 0.64) and 2.64 mU/L (95% 
CI 1.93, 3.34). 
Similarly, results for FT4 of the study cohort have also been re-calculated for the 
group reference range, LL =7.10 pmol/L (95% CI 5.36, 8.83) and UL =14.02pmol/L 
(95% CI 12.28, 15.75).  
Data derived from TPOAB results in this study has however been calculated. Out of 
585 of total participants, 546 (93.3%) showed negative results for TPO antibodies. 
Nevertheless, their TSH results range between 0.15mU/L (95% CI 0.84, 0.53) and 
2.6mU/L (95% CI 1.9, 3.3).  
TPO antibodies were tested positive only in 39/585 participants (6.6%). However, 
their TSH results are distributed between 0.04mU/L (95% CI 0.8, 0.76) and 
3.05mU/L (95% CI 2.27, 3.82). 
Calculation of cutoff values for TSH according to TPO status revealed almost 
0.5mU/L difference in favor of TPO positive group where only two of TSH results 
showed above 3.05mU/L and similar number of participants has UIC < 117ug/L 
without any identifiable association between them. However, because of the small 
number of positive TPO results, we cannot draw a valid conclusion without making 
unsubstantiated assumptions.  
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Table 3-9 Association of low thyroid status1 with various forms of anaemia, including microcytic (iron-
deficiency) anaemia 
Group2 N Group 
total 
% 
Group3 
% 
Total3 
Mean 
ferritin (SD) 
IRR4 95%CI P-value5 
No anaemia 9 256 3.5% 1.5% 18.8 (18.7) 1.00   
Normocytic anaemia 5 175 2.9% 0.8% 32.2 (105.0) 0.81 (0.28 to 2.39) >0.90 
Microcytic anaemia 4 134 3.0% 0.7% 8.3 (5.5) 0.85 (0.27 to 2.71) 0.78 
Macrocytic anaemia 4 25 16.0% 0.7% 31.1 (43.5) 4.55 (1.51 to 13.74) 0.022 
 
1 Low thyroid status defined as TSH>2.5. 
2 Women were classified as having: 1) No anaemia (Hb≥120); 2) Normocytic anaemia (Hb<120, MCV 85-96); 3) Microcytic 
anaemia (Hb<120, MCV <85 or Ferritin <10); 4) Macrocytic anaemia (Hb<120, MCV >96). 
3 Percentages were calculated as % of each group, and % of total (N=590) women. 
4 Likelihood of occurrence of low thyroid status was estimated as incidence rate ratio (IRR; 95% confidence intervals; P-values) 
using Poisson regression with no covariates. 
5 P-values were adjusted for multiple comparisons using the Holm method. 
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3.3.4 Cord blood TSH 
Cord blood samples of 402/615 (65%) babies were collected and the reasons for low 
percentage in cord blood collection were; either due to insufficient samples or simply 
forgotten during labour chaos. Cord TSH results in table 3.10 (Mean 8.11; 95% CI -
2.74 to 0.4; P= 0.008) of 121 babies born by operative lower segment Caesareans 
section (LSCS), demonstrate relatively lower TSH levels compared to results of 
babies  born by instrumental support or those who were born normally.  
 
Table 3-10 reflects results of babies born to participants with bleeding complications 
(APH/IPH), show lower estimates compared to participants without bleeding (Mean 
(SD) 4.91(2.16); 95% CI -5.48 to -2.48; P < 0.001). Similarly, the same table shows 
that cord TSH results of babies born to women with previous history of pregnancy 
are slightly lower compared to those who were born to first time pregnant 
participants. 
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Table 3-10 Association between predictor variables and levels of cord TSH1 
 
 N Mean (SD) 2 Mean Δ2 95%CI P-value 
Normal thyroid 387 9.27 (5.92) 0.00   
Low thyroid 15 9.81 (6.66) 0.45 (-2.62 to 3.53) 0.77 
Normal vaginal delivery 222 9.73 (6.22) 0.00   
Instrumental delivery 59 10.07 (6.89) -0.38 (-2.35 to 1.58) 0.70 
LSCS4 121 8.11 (4.67) -1.57 (-2.74 to -0.41) 0.008 
No history 367 9.21 (5.98) 0.00   
History of prematurity 35 10.17 (5.60) 1.53 (-0.39 to 3.45) 0.12 
No haemorrhage 392 9.40 (5.97) 0.00   
APH or IPH 10 4.91 (2.16) -3.98 (-5.48 to -2.48) <0.001 
Normal labour 396 9.33 (5.96) 0.00   
Prolonged labour 6 6.74 (3.75) -2.09 (-5.14 to 0.96) 0.18 
Primigravida 145 10.43 (6.72) 0.00   
Multigravida 257 8.65 (5.36) -1.92 (-3.23 to -0.62) 0.004 
Log10 Hb (reg. coef3) 402 2.07 (0.03) 0.53 (0.08 to 0.99) 0.022 
 
1 Cord TSH measurements were collected in 402 patients 
2 The mean (standard deviation) and mean difference between presence or absence of predictor variables was estimated using 
general linear modelling (95% confidence intervals; P-values). Predictor variables to be included in the model were selected 
using backwards stepwise regression (P-value for removal = 0.22; P-value for entry = 0.12), with low thyroid status as a 
forced entry variable. For the categorical variables, the base comparator variable is assigned a mean difference of 0. 
3 For haemoglobin, log10 transformation was used due to non-normal distribution, and this value was further transformed as a 
z-score ((Hb-mean)/SD): the regression coefficient (95% confidence intervals; P-value) shown is the rise in cord TSH 
associated with each 1 standard deviation rise in Log10 Hb. 
4 No difference in the mean difference of cord TSH was seen between emergency (N=43) and elective (N=78) lower segment 
Caesarean section (0.01; 95%CI 2.03 to -2.02; P>0.90)
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4 DISCUSSION AND CONCLUSION  
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This study has demonstrated that approximately 3.4% of the Northern Tasmanian 
women could be at risk of developing thyroid dysfunction during their pregnancy 
with (TSH>2.5-3mU/L and >3mU/L) when measured between end of the second 
trimester and start of the third. Additionally, 12.3% of the same pregnant population 
could be labelled with the controversial status of (Isolated Hypothyroxinemia) when 
applying <8.9pmol/L for FT4 as a cut-off. The results also suggest that antenatal 
complications defined in this study are not associated with low thyroid status. The 
outcomes of this study also suggest that the risk for experiencing prolonged labour as 
an intra-natal complication can be increased up to three-fold with low thyroid status 
(IRR 3.31; 95% CI 1.13 to 9.69; P= 0.029).  
 
There was no positive association between iron deficiency anaemia (IDA) and low 
thyroid status could be demonstrated in this thesis. This study was not able to clearly 
demonstrate whether a symptom based risk score for thyroid dysfunction during 
pregnancy would be better than biochemical screening. Although CB-TSH 
demonstrated a positive association with maternal complications (IPH), its role in 
assessing foetal thyroid status has not been established. A 41% of the study 
population had iodine deficiency during pregnancy and 11.2% of this subpopulation 
developed isolated hypothyroxinemia. 
 
Despite more than 2200 subjects being approached to enrol in the study, the consent 
rate was relatively low (28%). The main reason for this is most likely to be the 
single-centred study design, as well as the general lack of awareness of the 
consequences of iodine deficiency within the targeted study population. Although it 
was expected that the incidence rate of low thyroid function during pregnancy would 
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be higher than 3.4%, this is in line with internationally estimated figures for 
subclinical hypothyroidism in pregnancy (1.5-4 %), (Allan et al., 2000, Casey et al., 
2005, Negro and Mestman, 2011). Furthermore, the results of this study suggest that 
the rate of prolonged labour as an intra-natal complication was greater in pregnant 
women with decreased thyroid function (IRR 3.31; 95% CI 1.13 to 9.69; P= 0.029). 
 
There has been conflicting reports on the association between gestational diabetes 
and hypothyroidism (Casey et al., 2007, Cleary-Goldman et al., 2008, Korevaar et 
al., 2013). No clear association (P= 0.36) between these were shown in the current 
study. It has previously been suggested that finding associations between 
complications occurring during pregnancy and thyroid function disorder was a 
difficult task (Negro and Mestman, 2011). Furthermore, it has been reported that 
inappropriate sample size is a common problem which occurs while investigating 
complication rates in overt or subclinical hypothyroidism during pregnancy (Negro 
and Mestman, 2011). These are in agreement with the current study. 
 
Although epidemic goitre is a strong part of Tasmanian history, the main culprit 
(iodine deficiency) remains persistent (Gibson, 2006, Burgess et al., 2007). It has 
also been reported that iodine deficiency is the main reason for subclinical 
hypothyroidism (SH) in iodine deplete areas (de Benoist et al., 2003, Hynes et al., 
2004, Li et al., 2006, Andersson et al., 2007, Vanderpump, 2010). Despite iodine-
fortification in Tasmania being mandatory, a nine year follow-up study of school-
aged children who were born to iodine deficient mothers were found to have 
difficulties in reading and grammar when compared to peers of the same age 
(Burgess et al., 2007, Hynes et al., 2013).  
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The symptom-based risk score using commonly accepted indicators of thyroid 
dysfunction has some ability to differentiate low and normal thyroid status. There 
doesn’t appear to be clear rationale for the variables included in the risk score. It may 
require orders of magnitude larger patient groups to reliably identify all the possible 
symptomatic expressions of low thyroid status. Also, the relatively small numbers of 
patients found with low thyroid status, as well as the relatively unstable estimates 
associated with nearby alternative thresholds, means that uncertainties around the 
usefulness of the risk score need to be considered.  
 
The estimation of the coefficients to be included in the risk score, and the calculation 
of the patient risk scores for the purpose of evaluation of efficacy of differentiation 
were performed on the same patients, rather than on two separate groups, as would 
be preferable (due to insufficient numbers of patients with low thyroid status). A 
broader objection to this particular expression of a symptomatic screening test for 
potential low thyroid status is that it was not conducted completely in a primary 
antenatal clinic where pregnant women undergo a routine check-up from early 
gestational age with consequent follow-up throughout all pregnancy period.  
 
IDA during pregnancy has been previously reported to cause obstetric and neonatal 
complications as well as neuro-psychological development (Scholl and Hediger, 
1994, Brabin et al., 2001, Sachdev et al., 2005). A positive relationship between IDA 
and low thyroid function has also been shown (Zimmermann et al., 2000). Although 
the current study demonstrates low ferritin level in 32.7% of study participants, there 
is no evidence of associations with low thyroid status.  
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In contrast, macrocytic anaemia was reported in 4 of 22 (18%) of low thyroid status. 
In another study, 57.1% of participants with hypothyroidism were reported to have 
either microcytic or macrocytic anaemia (Omar et al., 2010), with similar findings 
different explanations reported by (Tudhope and Wilson, 1960, Fein and Rivlin, 
1975, Horton et al., 1976). Although causes of macrocytosis in the general 
population can vary, including drugs, alcoholism, hypothyroidism and bone marrow 
dysplasia, deficiency of vitamin-B12 and folate were most prevalent in the obstetric 
population (Van der Weyden and Campbell, 1988, Colon-Otero et al., 1992, Savage 
et al., 2000, Kaferle and Strzoda, 2009, Tripathi et al., 2012). Further studies are 
required to differentiate that macrocytosis found in this study subgroup of low 
thyroid status, against those caused by vitamin-B12 and folate deficiencies. 
 
The effect of iodine deficiency on the incidence of thyroid dysfunction has also been 
investigated. Although iodised salt has been promoted for the last decade and 
consumption of iodine-contained multi-vitamins, median urinary iodine of 117µg/L 
derived from study cohort results reflects deficiency according to WHO’s latest 
recommendations (World Health Organization, 2013).   While 11.2% of the study 
iodine deficient population was labelled with isolated hypothyroxinemia (IH), it was 
reported to be approximately of 25-30% in other iodine deficient population (Berbel 
et al., 2009, Moleti et al., 2009, Krassas et al., 2010).  
 
Normal reference range for FT4 in the general population provided by LGH 
pathology is 10.00-28.2pmol/L. Thus, considering the fact of physiological changes 
in the thyroid regulation that occur in pregnancy (discussed earlier), a lower cutoff 
was considered. Since there is no standard reference range to define 
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hypothyroxinemia, lower bound (<8.9pmol/L) of FR4 used in the study was a result 
of statistical assumptions. Nevertheless, now we can set our own reference range for 
FT4 based on study cohort results. Results of free thyroxin of the study cohort have 
been recalculated for the group reference range, LL =7.10pmol/L (95% CI 5.36, 
8.83) and UL =14.02pmol/L (95% CI 12.28, 15.75). 
 
Applying the group lower bound (<7.1) as a cutoff will result in a remarkable 
decrease in number of isolated hypothyroxinemia to only 1.47% (9/609). Further 
clinical studies are required to justify the validity these biomedical references. The 
relevance of iodine deficiency and IH with possible health consequences on foetal 
neuropsychological development were also investigated and published (Morreale de 
Escobar et al., 2000, Negro and Mestman, 2011). Although a recent publication 
reported a negative effect of maternal iodine deficiency on offspring’s reading 
ability, it was not verified whether IH was a contributing factor (Hynes et al., 2013). 
It is therefore recommended to follow-up of the iodine deficient population of this 
study, to determine whether neuropsychological consequences are due to iodine 
deficiency alone, IH alone or when combined.    
 
It has been suggested that maternal IH has no impact on normal IQ development of 
offspring, according to a recent study (Grau et al., 2015). In contrast, association 
between hypothyroxinemia and autism has been suggested (Román et al., 2013). 
Also, a survey review of the European clinical institutions resulted in lack of a 
standard approach regarding hypothyroxinemia in pregnancy (Vaidya et al., 2012). 
These reports encourage further follow-up of IH cases of this study to be considered. 
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Persistence of iodine deficiency in Tasmania was reported a decade ago. In view of 
this fact, it was hoped that mandatory fortification and awareness would halt this 
public health issue. Nevertheless, median UIC of 117ug/L of our pregnant 
participants still reflects inadequate iodine intake. According to the latest 
recommendation by WHO; an adequate iodine intake for pregnant women is best 
achieved when median UIC is between 150-249 µg/L levels (World Health 
Organization, 2013). Retrospective analysis of this population and data related to 
their diet maybe required in order to investigate the causes and factors contributed to 
this result. Also, comparing this outcome with a non-pregnant population will lead to 
determine individual factors from combined ones.  
 
Neonatal hypothyroidism causes serious neurological disorder in children. It is 
relatively rare, affecting one in 3500-4000,  the diagnosis is conducted by screening 
neonatal TSH in the venous blood obtained via heel prick (Grueters and Krude, 
2006). As symptoms and signs are indistinguishable at early infancy, it is essential to 
initiate this biochemical neonatal screening for early diagnosis and treatment 
(Vanderpump, 2010). Cord blood is accessible via normal or operative deliveries, 
testing for TSH in the cord blood (CB-TSH) was thought to be a less invasive 
alternative in this study.  
 
Although there are no general standardised normal values for CB-TSH, 
recommendations for a cut off value vary between 20mU/L and  14mU/L (Manglik 
et al., 2005). Variable levels of CB-TSH according to type of delivery as well as 
according to history of previous pregnancy have been demonstrated in this study. 
Since low cord TSH results for babies born by LSCS and for babies born to first time 
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pregnancy (Table 3-11) can’t be explained at this stage, investigating the role of 
anaesthesia and stress on the thyroid in non-pregnant and during delivery, may help 
to clarify the variable levels of CB-TSH.  
 
A decrease of more than 50% in results of CB-TSH of ten babies born to participants 
who suffered IPH/APH was demonstrated, compared to babies born without maternal 
complications (Table 3-10). Although this may not reflect low thyroid status in the 
newborn babies, they do demonstrate strong variability in reaction of the foetal 
thyroid towards different maternal obstetric conditions (ante-/intra-partum bleeding). 
 
A number of factors limited this study. The major limitation lies within the design of 
the study; single-centre recruitment lead to a small selected group. Analysing data in 
small numbers, made it difficult to determine whether increases in complication rates 
were statistically significant. The absence of parallel clinical assessment by an 
obstetrician for all pregnant women, made a comparison between case selective and 
generalised screening not feasible in this study. In addition, circadian variation of UI 
keeps the question of over-estimation or under-estimation wide open. 
 
The number of cord blood samples collected was low, possibly due to unpredictable 
labour times. Lack of own method-specific and trimester specific reference range for 
TFT in pregnancy that could add more specificity to the study. Using more 
sophisticated screening tools like chromatography/tandem-mass spectrometry 
(LC/MS/MS) was not available.   Analysis of cord blood TSH results could have 
been of more value if compared against neonatal TSH results for the same babies.  
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A larger scale study is clearly required to determine the true incidence of pregnancy 
complications (including gestational diabetes and prolonged labour) in women with 
low thyroid function in Tasmania. A valid comparison between well implemented 
symptom-based risk score and biochemical screening is feasible with a collective 
team work between pathology and ante natal clinic. A retrospective analysis can 
compare cord TSH of this study with the neonatal TSH to determine potential 
associations. A positive association may reveal CB-TSH as a valid alternative for the 
current neonatal screening. In addition, a retrospective study investigating detailed 
diet of the cohort may reveal causes of iodine deficiency found in this pregnant 
population.  
  
Furthermore, calculation of cutoff values for TSH according to the TPO status 
revealed almost 0.5mU/L difference in favor of TPO positive group where only two 
of TSH results showed above 3.05mU/L and similar number of participants has UIC 
< 117ug/L without any identifiable association between them. However, because of 
the small number of positive TPO results, we cannot draw a valid conclusion without 
making unsubstantiated assumptions. When applying the upper bound of TSH (>2.6) 
derived from the study cohort with TPO-ve, 4.95% (27/546) of these participants 
may be at risk of developing thyroid dysfunction regardless being negative to TPO 
antibodies. Since the original study was not designed to set TSH reference ranges 
according to TPO status, applying this in future studies is strongly warranted in order 
to find their significance and validity for this specific population. 
 
In conclusion, this study demonstrates that a small percentage of pregnant women 
living in iodine-poor Tasmania are prone to thyroid dysfunction. Complications that 
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may occur during pregnancy and delivery could be due to low thyroid function, but 
was not able to be clearly proven in this study. Although prior or early-pregnancy 
testing for iodine level and thyroid function can help early identify iodine deficiency 
and thyroid disorder, justifying a general screening will require further studies with 
multicentre-recruitment and ante-natal clinics involvement. Approving the use of 
cord blood as a screening tool for neonatal hypothyroidism will require further work. 
This includes comparing current CB-TSH results with neonatal TSH to determine a 
valid association. Further investigation is also required to determine whether the 
unexpected association between CB-TSH and IPH/APH is a constant relationship, 
not raised by chance. 
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